| Excerpt | Reference |
|---|
| "NAFLD is associated with lower serum adiponectin levels independent of conventional cardiovascular risk factors in Asian Indians known to have high prevalence of diabetes and coronary artery disease." | ( Anjana, RM; Anuradha, S; Gokulakrishnan, K; Indulekha, K; Mohan, V, 2010) |
| "The pathogenesis of NAFLD is currently unknown, but accumulating data suggest that oxidative stress and altered redox balance play a crucial role in the pathogenesis of steatosis, steatohepatitis, and fibrosis." | ( Cassader, M; Gambino, R; Musso, G, 2011) |
| "NAFLD is considered as the liver component of metabolic syndrome and is linked to accelerated atherosclerosis and cardiovascular disease." | ( Abu Bakar, MR; Ansari, MA; Gopalan, Y; Karim Khan, NA; Lutfi Shuaib, I; Magosso, E; Nesaretnam, K; Ng, BH; Wong, JW; Yuen, KH, 2010) |
| "Pediatric NAFLD is an underdiagnosed condition which can result in significant liver injury including cirrhosis." | ( Lavine, JE; Mencin, AA, 2011) |
| "Nonalcoholic fatty liver disease is associated with the metabolic syndrome." | ( Allard, JP; Arendt, BM, 2011) |
| "As NAFLD is a very common condition, future work in this field is needed with regard to a more practical definitive diagnosis, evidence- based treatments and a better understanding of the possible links between NAFLD, elevated SUA levels, cardiovascular disease and chronic kidney disease." | ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2011) |
| "PPARγ role in nonalcoholic fatty liver disease is controversial because PPARγ overexpression is a general property of steatotic livers, but its activation by thiazolidinediones reduces hepatic steatosis." | ( Arroyo, V; Barak, Y; Clària, J; García-Alonso, V; González-Périz, A; López-Parra, M; López-Vicario, C; Martínez-Clemente, M; Morán-Salvador, E; Titos, E, 2011) |
| "Both T2DM and NAFLD are associated with adverse outcomes of the other; T2DM is a risk factor for progressive liver disease and liver-related death in patients with NAFLD, whereas NAFLD may be a marker of cardiovascular risk and mortality in individuals with T2DM." | ( Adams, LA; Smith, BW, 2011) |
| "NAFLD is frequent in obese women without any other health condition that could interfere with COC eligibility criteria, especially in those with PCOS." | ( Ferriani, RA; Martins, WP; Vieira, CS; Zueff, LF, 2012) |
| "NAFLD is linked to a wide spectrum of diseases including obesity and diabetes that are increasingly prevalent in Western populations." | ( Chaba, T; Jacobs, RL; Ling, J; Vance, DE; Zhu, LF, 2012) |
| "The mechanisms of NAFLD are not fully understood, but insulin resistance has been proposed as a key determinant." | ( Abrahamian, GA; Bastarrachea, RA; Casiraghi, F; Chavez, AO; Cline, GW; Comuzzie, AG; Davalli, AM; DeFronzo, RA; Dick, EJ; Folli, F; Gastaldelli, A; Guardado-Mendoza, R; Halff, GA; Higgins, PB; Jimenez-Ceja, LM; Kamath, S; Mattern, V; Paez, AM; Ricotti, A; Rodriguez-Sanchez, IP; Tejero, ME; Tripathy, D, 2011) |
| "Although NAFLD is a benign form of liver dysfunction, it can proceed to a more serious condition, nonalcoholic steatohepatitis (NASH), which may lead to liver cirrhosis and hepatocellular carcinoma." | ( Nomura, K; Yamanouchi, T, 2012) |
| "Murine NAFLD is associated with portal hypercortisolism and11β-HSD1 overexpression in VAT." | ( Arrese, M; Baudrand, R; Boza, C; Candia, R; Carrasco, G; Carvajal, CA; Cerda, J; Escalona, A; Fardella, CE; Morales, M; Padilla, O; Pérez, G; Pizarro, M; Riquelme, A; Solís, N, 2012) |
| "Nonalcoholic fatty liver disease is a chronic metabolic disorder with significant impact on cardiovascular and liver mortality." | ( Bucchieri, F; Bugianesi, E; Galvano, F; Li Volti, G; Mangiameli, A; Marino Gammazza, A; Marino, A; Parola, M; Paternostro, C; Salamone, F; Tibullo, D, 2012) |
| "Nonalcoholic fatty liver is characterized by the fatty deformation and lipid deposition of hepatic parenchymal cells that are associated with cardiometabolic diseases." | ( Chen, J; Feng, X; Li, L; Liu, D; Ni, Y; Nilius, B; Sun, J; Wang, P; Yan, Z; Yu, H; Zhao, Z; Zhu, Z, 2012) |
| "Liver with NAFLD is more sensitive to hepatotoxicity; furthermore, the disrupted balance of oxidative stress and anti-oxidant defense contributes to the underlying mechanisms." | ( Ge, YL; Ji, G; Li, DF; Liu, P; Liu, T; Mao, ZM; Song, HY; Yang, LL; Zhang, L; Zhang, XQ; Zheng, PY, 2011) |
| "Nonalcoholic fatty liver disease is characterized by chronic liver damage and can develop into liver cirrhosis." | ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012) |
| "NAFLD is characterized by both triglyceride and free cholesterol (FC) accumulation without a corresponding increment in cholesterol esters." | ( Contos, MJ; Fuchs, M; Kapoor, A; Kellum, J; Maher, J; Min, HK; Mirshahi, F; Sanyal, AJ; Warnick, R; Zhou, H, 2012) |
| "NAFLD is strongly linked to insulin resistance and is considered the hepatic manifestation of the metabolic syndrome." | ( Fletcher, JA; Matthew Morris, E; Rector, RS; Thyfault, JP, 2013) |
| " NAFLD is the commonest liver disease in Indian psoriatic patients when compared to controls." | ( Anandan, S; Madanagobalane, S, 2012) |
| "In Asian Indians NAFLD is significantly associated with subclinical atherosclerosis and endothelial dysfunction independent of obesity and metabolic syndrome." | ( Bhatt, SP; Guleria, R; Kumar, A; Luthra, K; Pandey, RM; Sharma, S; Thakur, ML; Vikram, NK, 2012) |
| "In addition, NAFLD is an independent predictor for diabetic macroangiopathy." | ( Abe, M; Antoku, S; Ito, H; Komatsu, Y; Mifune, M; Oshikiri, K; Takeuchi, Y; Togane, M, 2012) |
| "Nonalcoholic fatty liver disease is becoming an epidemic." | ( Matherly, SC; Puri, P, 2012) |
| "The etiology of NAFLD is multifactorial." | ( Burnol, AF; Dubuquoy, C; Moldes, M, 2013) |
| "The prevalence of NAFLD is likely to increase over time due to the epidemics of obesity and diabetes." | ( Pacana, T; Sanyal, AJ, 2012) |
| "PNPLA3 NAFLD is characterised by an increase in liver fat but no insulin resistance or AT inflammation, while obese NAFLD has all three of these features." | ( Hakkarainen, A; Lallukka, S; Lundbom, N; Olkkonen, VM; Orho-Melander, M; Perttilä, J; Sevastianova, K; Yki-Järvinen, H, 2013) |
| "NAFLD is associated with cardiometabolic risk factors and is the most common chronic liver disease among adults in the Western Hemisphere." | ( Bell, AM; Byrd, JS; Malinowski, SS; Riche, DM; Wofford, MR, 2013) |
| "The hallmark of NAFLD is steatosis of unknown etiology." | ( Comhair, TM; Dejong, CH; Gaemers, I; Garcia-Caraballo, SC; Hakvoort, TB; Houten, SM; Koehler, SE; Lamers, WH; Schaap, FG; Verheyen, F, 2013) |
| "NAFLD is associated with decreased Ln SDNN and increased 0 V percentage." | ( Chan, CC; Chen, CH; Ho, YL; Hung, CS; Lee, YC; Lin, C; Lin, YH; Liu, YC; Lo, MT; Ma, HP; Wu, YW, 2013) |
| "Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests." | ( Ando, Y; Hamajima, N; Hashimoto, S; Ichino, N; Inoue, T; Ohashi, K; Osakabe, K; Sawada, A; Sugimoto, K; Suzuki, K; Teradaira, R; Yamada, H, 2013) |
| "NAFLD is also associated with increased risk of cardiovascular diseases, hyperlipidemia, and type 2 diabetes." | ( Guan, Y; Yang, J, 2013) |
| "Nonalcoholic fatty liver disease is associated with obesity and insulin resistance." | ( Lang, M; Lu, J; Min, X; Qian, H; Wang, N; Wang, Y; Yang, H; Zhang, P; Zhang, Y; Zhang, Z, 2013) |
| "NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis." | ( Anstee, QM; Day, CP, 2013) |
| "NAFLD is characterized by hepatic triglyceride (TG) infiltration in the absence of alcohol abuse or chronic liver disease." | ( Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP, 2014) |
| "NAFLD is a common feature of metabolic syndrome being often associated with obesity, dyslipidemia and diabetes and mostly closely linked to insulin resistance." | ( Brenner, C; Calamita, G; Fanelli, E; Frühbeck, G; Gena, P; Marinelli, RA; Mastrodonato, M; Mentino, D; Portincasa, P; Rodríguez, A; Svelto, M, 2013) |
| "Nonalcoholic fatty liver disease is one of the most common hepatic disorders worldwide." | ( Krawczyk, M; Lammert, F; Portincasa, P, 2013) |
| "In addition, NAFLD is a risk factor for the development of other serious diseases, such as diabetes or cardiovascular disease." | ( Abe, M; Furukawa, S; Hiasa, Y; Hirooka, M; Kumagi, T; Matsuura, B; Miyake, T; Onji, M; Tokumoto, Y, 2013) |
| "Pharmacotherapy in NAFLD is not well validated, particularly combination therapy." | ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| "NAFLD is a major form of chronic liver disease that is highly prevalent in obese and overweight adults and children." | ( Ip, BC; Wang, XD, 2013) |
| "Liver steatosis in nonalcoholic fatty liver disease is affected by genetics and diet." | ( Asai, A; Bu, HF; Chou, PM; DiDonato, CJ; Jiang, A; Rao, MS; Tan, XD; Wang, X, 2014) |
| "NAFLD is common in the population and in certain sub groups (e." | ( Bhatia, L; Byrne, CD; Calder, PC; Clough, GF; McCormick, KG; Nash, K; Scorletti, E, 2014) |
| "NAFLD is regarded unquestionably as one of the components of the metabolic syndrome." | ( Pirola, CJ; Sookoian, S, 2014) |
| "Nonalcoholic fatty liver disease is the most common cause of chronic liver disease in Western countries, and consists of a spectrum of histopathological changes that range in severity from simple steatosis to steatohepatitis to cirrhosis." | ( Loomba, R; Pearlman, M, 2014) |
| "Treatment of NAFLD is still in its infancy, although large controlled studies have demonstrated some efficacy for pioglitazone or vitamin E." | ( Moschen, AR; Tilg, H, 2014) |
| "NAFLD is supposed to be initiated by the accumulation of lipids in the liver, which finally results in an impaired hepatic insulin signalling." | ( Alisi, A; Bruscalupi, G; Gnocchi, D; Incerpi, S; Massimi, M, 2014) |
| "NAFLD is the liver manifestation of metabolic syndrome (MS)." | ( Drazilová, S; Fedacko, J; Gecková, AM; Janicko, M; Jarcuska, P; Kristian, P; Mareková, M; Pella, D; Senajová, G; Siegfried, L; Tkác, M; Veselíny, E, 2014) |
| "NAFLD is defined as a hepatic steatosis observed on liver ultrasonography in the absence of a second cause." | ( Chen, Y; Liu, PJ; Lou, HP; Ma, F; Zhu, YN, 2014) |
| "NAFLD is observed in many patients with Metabolic Syndrome." | ( Avalueva, EB; Ivanov, SV; Lapinskiĭ, IV; Orishak, EA; Skazyvaeva, EV; Tkachenko, EI, 2013) |
| "Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity." | ( Chui, PC; Cunniff, JC; Fisher, FM; Flier, JS; Kharitonenkov, A; Lundasen, T; Maratos-Flier, E; Nasser, IA; Popov, Y; Schuppan, D, 2014) |
| "Although NAFLD is a major cause of cirrhosis and cancer of the liver of unknown cause, no established pharmacological treatment for NAFLD has been established yet." | ( Aizawa-Abe, M; Aotani, D; Ebihara, C; Ebihara, K; Gumbilai, VM; Hosoda, K; Kusakabe, T; Nakao, K; Nishio, M; Sakai, T; Suzuki, A; Yamamoto, Y; Yamamoto-Kataoka, S; Zhao, M, 2015) |
| "In conclusion, NAFLD is a common clinical problem that places children at substantial risk for high blood pressure, which may often go undiagnosed." | ( Behling, C; Donithan, M; Hallinan, EK; Newton, KP; Schwimmer, JB; Tonascia, J; Xanthakos, SA; Zepeda, A, 2014) |
| "NAFLD is probably a heterogeneous disease and IR is not the sole factor responsible for NAFLD; further studies are needed to find out other possible etiological factors." | ( Agrawal, O; Bhuyan, P; Kar, SK; Meher, C; Misra, B; Misra, D; Panigrahi, MK; Pattnaik, K; Rout, N; Singh, SP; Swain, M, 2015) |
| "Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia." | ( Anstee, QM; Day, CP; Hardy, T, 2015) |
| "Development of NAFLD are associated with obesity and excess body weight, phenomenon of leptinresistance arises to patients with obesity and can be considered as predictor of the development and progression of NAFLD among this category of patients." | ( Lapteva, IV; Livzan, MA; Miller, TS, 2014) |
| "NAFLD is the commonest cause of chronic liver disease." | ( Noureddin, M; Rinella, ME, 2015) |
| "Nonalcoholic fatty liver disease is a common cause of liver related morbidity and mortality." | ( Sanyal, AJ, 2015) |
| "Nonalcoholic fatty liver disease is associated with chronic oxidative stress." | ( Burian, M; Cahova, M; Cervinkova, Z; Dankova, H; Drahota, Z; Gladkova, C; Kazdova, L; Krizova, J; Kucera, O; Oliyarnyk, O; Palenickova, E; Papackova, Z; Sticova, E; Stopka, P, 2015) |
| "NAFLD is strongly associated with metabolic syndrome, but several other entities play a role in the pathogenesis of NAFLD more than metabolic syndrome." | ( Kara, M; Tanoglu, A, 2015) |
| "Nonalcoholic steatohepatitis is a common finding in patients with CVD." | ( Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A, 2015) |
| "Nonalcoholic fatty liver disease is characterized by substantial interpatient variation in rate of progression and disease outcome: Although up to 25% of the general population are at risk of progressive disease, only a minority experience associated liver-related morbidity." | ( Anstee, QM; Day, CP, 2015) |
| "Nonalcoholic fatty liver disease is associated with metabolic syndrome and has the unique characteristic of excess lipid accumulation in liver." | ( Choi, JM; Im, JH; Jun, DW; Kang, KW; Kim, HS; Kim, JW; Kim, SK; Lee, K; Lim, SC; Yang, JW, 2016) |
| "NAFLD is closely correlated with baPWV, particularly in females." | ( Chen, JH; Chen, LY; Dai, HL; Fang, LZ; Lu, CR; Qiao, QH; Zhu, WH, 2015) |
| "NAFLD is recognized as a major cause of liver-related morbidity and mortality." | ( Braddock, M; Liu, WY; Lu, QD; Shi, KQ; Song, D; Sun, DQ; Wu, SJ; Zheng, MH; Zhu, GQ, 2016) |
| "The prevalence of NAFLD is more affected by the G allele of patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 in normal weight (odds ratio (OR) 3." | ( Itoh, Y; Kadotani, H; Kamaguchi, M; Kobayashi, M; Mochizuki, N; Nishimura, T; Nishioji, K; Sumida, Y; Yamaguchi, K, 2015) |
| "NAFLD is now the most common cause of chronic liver disease in developed countries and is defined as excessive lipid accumulation in the liver, that is, hepatosteatosis." | ( Depner, CM; Jump, DB; Lytle, KA; Tripathy, S, 2015) |
| "Nonalcoholic fatty liver disease is correlated albeit imperfectly with obesity and other metabolic diseases such as diabetes, hyperlipidemia, and cardiovascular disease, but exactly how having one of these diseases contributes to the development of other metabolic diseases is only now being elucidated." | ( Halligan, B; Kahali, B; Speliotes, EK, 2015) |
| "Nonalcoholic fatty liver disease is an obesity-related disorder characterized by lipid infiltration of the liver." | ( Cox-York, K; Estrada, AL; Foster, MT; Gentile, CL; Miller, T; Pagliassotti, MJ; Reese, L; Wang, D; Wei, Y; Weir, TL, 2016) |
| "NAFLD is currently one of the most common etiologies of chronic liver disease worldwide." | ( Jesudoss, VA; Muniandy Narayanan, J, 2016) |
| "NAFLD is increasing in prevalence and is presently the second most frequent indication for liver transplantation." | ( Byrne, CD; Wainwright, P, 2016) |
| "Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in Western countries and an independent risk factor for atherosclerotic heart disease." | ( Altun, A; Çevik, H; Eroğlu, H; Gülmez, Ö; Oğuz, D; Ünal, HÜ, 2016) |
| "NAFLD is prevalent in Chinese population with a rapidly increasing tendency." | ( Chen, XH; Li, YL; Lu, ZY; Shao, Z; Wulasihan, M, 2016) |
| "NAFLD is the most common liver disease in developed countries." | ( Hannah, WN; Harrison, SA, 2016) |
| "Nonalcoholic fatty liver disease is the most common cause of liver disease in the United States." | ( Hameed, B; Terrault, N, 2016) |
| "Patients with NAFLD are at increased risk of more aggressive liver disease (non-alcoholic steatohepatitis [NASH]) and at a higher risk of death from cirrhosis, hepatocellular carcinoma and cardiovascular disease." | ( Cusi, K, 2016) |
| ""Obese/Metabolic NAFLD" is closely associated with obesity and insulin resistance and therefore predisposes to type 2 diabetes and cardiovascular disease." | ( Petäjä, EM; Yki-Järvinen, H, 2016) |
| "NAFLD is likely to become the most common cause of chronic liver disease." | ( Gaïa, N; Genton, L; Golay, A; Lazarevic, V; Pataky, Z; Pichard, C; Rubbia-Brandt, L; Schrenzel, J; Spahr, L; Terraz, S, 2016) |
| "Furthermore, NAFLD is associated with the presence of metabolic syndrome, type 2 diabetes, and atherosclerosis." | ( Adinolfi, LE; Giordano, M; Guerrera, B; Marrone, A; Restivo, L; Rinaldi, L; Zampino, R, 2016) |
| "Nonalcoholic fatty liver disease is currently the most common chronic liver disease worldwide, characterized by excessive hepatic lipid accumulation without significant ethanol consumption." | ( Akagawa, M; Kai, K; Kamikubo, R; Tsuji-Naito, K, 2016) |
| "NAFLD is now the most common cause of liver disease in Western countries." | ( Angus, PW; Furness, JB; Leung, C; Rivera, L, 2016) |
| "NAFLD is considered a hepatic manifestation of metabolic syndrome; however, mechanisms underlying the onset and progression of NAFLD are still unclear." | ( Nagashimada, M; Ni, Y; Ota, T; Zhuge, F, 2016) |
| "Nonalcoholic steatohepatitis is a variable in drug disposition, yet the impact on renal transport processes has yet to be fully understood." | ( Cherrington, NJ; Clarke, JD; Dzierlenga, AL; Goedken, M; Klein, DM; Laho, T; Li, H; Micuda, S, 2016) |
| "NAFLD is commonly associated with features of the metabolic/insulin resistance syndrome ('Metabolic/Obese NAFLD') and may therefore predict type 2 diabetes (T2DM)." | ( Lallukka, S; Yki-Järvinen, H, 2016) |
| "Children with NAFLD are at risk for early renal dysfunction." | ( Andreoli, GM; Bonci, E; Chiesa, C; De Luca, E; Di Martino, M; Gallozzi, A; Pacifico, L, 2016) |
| "NAFLD is characterized by a wide range of liver changes, from simple steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma." | ( Chen, G; Nagata, N; Ni, Y; Ota, T; Xu, L, 2016) |
| "NAFLD is considered to be a series of complex, multifaceted pathological processes involving oxidative stress, inflammation, apoptosis, and metabolism." | ( Peng, JY; Qi, Y; Qiao, YJ; Tao, XF; Xu, LN; Yao, H; Yin, LH; Zhao, YL, 2016) |
| "NAFLD is further favored by the patatin-like phospholipase domain-containing 3 (PNPLA3) p." | ( Alustiza, JM; Banales, JM; Bujanda, L; Emparanza, JI; Jiménez-Agüero, R; Krawczyk, M; Lammert, F; Perugorria, MJ, 2016) |
| "NAFLD is a "hot potato" for pharmaceutical companies." | ( Jun, DW; Nguyen, MH; Oh, H; Saeed, WK, 2016) |
| "Nonalcoholic fatty liver disease is very frequent in type 2 diabetes, with increased risk of further development of liver fibrosis." | ( Bouillet, B; Cercueil, JP; Chevallier, O; Denimal, D; Duvillard, L; Fourmont, C; Loffroy, R; Petit, JM; Vergès, B, 2017) |
| "NAFLD is considered a multifactorial disease and a clinically relevant hepatic manifestation of metabolic syndrome." | ( Johnston, TP; Pirro, M; Sahebkar, A; Zabihi, NA, 2017) |
| "The morbidity of NAFLD is seeing an increase year by year in the world, and it is a common cause of chronic hepatic disease and lacks effective treatment." | ( Lu, LG; Ma, ZZ, 2016) |
| "The prevalence of NAFLD is high in men with hypogonadism, including those with idiopathic hypogonadotropic hypogonadism (IHH), as well as in women in post-menopause, those under estrogen receptor antagonist treatment or women with Turner syndrome." | ( Goulis, DG; Mintziori, G; Poulakos, P; Tsametis, C, 2017) |
| "NAFLD is a clinically progressive disease with steatosis, inflammation, endothelial dysfunction and fibrosis being the stages where clinical intervention becomes necessary." | ( Alhasson, F; Bell, PD; Chandrashekaran, V; Chatterjee, S; Das, S; Dattaroy, D; Diehl, AM; Liedtke, W; Michelotti, G; Nagarkatti, M; Nagarkatti, P; Seth, RK, 2017) |
| "Nonalcoholic steatohepatitis is a common liver disease that is often accompanied by dysregulated iron metabolism." | ( Bergmann, OM; Bloomer, SA; Broadhurst, KA; Brown, KE; Hicsasmaz, H; Mathahs, MM; Olivier, AK, 2016) |
| "Nonalcoholic fatty liver disease is considered a disorder of the endoplasmic reticulum (ER) and mitochondria." | ( An, W; Xiao, F; Zhang, C; Zhang, J, 2017) |
| "NAFLD is a manifestation of metabolic syndrome affecting about one-third of the population worldwide and has progressive pathological potential for liver cirrhosis and cancer through non-alcoholic steatohepatitis (NASH)." | ( Alwahsh, SM; Gebhardt, R, 2017) |
| "NAFLD is becoming a major liver disease in Eastern countries and it is related to insulin resistance and metabolic syndrome." | ( Costa, SM; Couto, CA; Lisboa, QC, 2016) |
| "NAFLD is currently the most chronic liver disease due mainly to high-calorie consumption and lower physical activity." | ( Ibdah, JA; Nassir, F, 2016) |
| "Nonalcoholic fatty liver disease is growing in prevalence worldwide." | ( Chow, MD; Guo, GL; Lee, YH, 2017) |
| "Nonalcoholic fatty liver disease is one of the most common liver diseases in the world and is a typical hepatic manifestation of metabolic syndrome which is characterized with lipid accumulation in liver." | ( Deng, KY; Guan, XH; Hu, L; Huang, CC; Qian, YS; Wang, LF; Wang, XN; Xiao, YF; Xin, HB, 2017) |
| "Because NAFLD is a multifaceted disorder with many underlying metabolic abnormalities, currently, there is no pharmacological agent that is therapeutically approved for the treatment of this disease." | ( O, K; Sid, V; Siow, YL, 2017) |
| "The pathogenesis of NAFLD is complex and multifactorial." | ( Baldelli, E; Ballestri, S; Lonardo, A; Marrazzo, A; Nascimbeni, F; Romagnoli, D, 2017) |
| "NAFLD is closely linked with hepatic insulin resistance." | ( Samuel, VT; Shulman, GI, 2018) |
| "NAFLD is influenced by genetic factors, and the heritability has been estimated at 0." | ( Boonvisut, S; Iwamoto, S; Miyashita, H; Nakayama, K; Watanabe, K; Yoshida, K, 2017) |
| "NAFLD is emerging as the major etiological contributing factor for non-B non-C HCC in India." | ( Abraham, P; Bharath Kumar, C; Burad, D; David, D; Eapen, CE; Goel, A; Joseph, P; Kodiatte, TA; Raghavendran, A; Ramachandran, J; Ramakrishna, B, 2017) |
| "The progression of NAFLD is complex and associated with inflammation, oxidative stress, autophagy, endoplasmic reticulum stress, and insulin resistance." | ( Du, L; Sun, Y; Teng, T; Tian, YZ; Wang, H; Wang, L; Wang, SG; Yin, XX; Zhou, M; Zhu, YY, 2017) |
| "Moreover, NAFLD is a systemic condition, featuring metabolic, cardiovascular and (hepatic/extra-hepatic) cancer risk." | ( Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L, 2017) |
| "NAFLD is strongly associated with MS, the components of which include abdominal obesity, hyperglycemia, hypertension, and dyslipidemia." | ( Kim, D; Kim, WR; Touros, A, 2018) |
| "Nonalcoholic fatty liver disease is emerging as the most common cause of chronic liver disease worldwide." | ( Bernstein, DE; Lim, HW, 2018) |
| "NAFLD is the most common chronic liver disease in the United States, ranging from fatty liver to steatohepatitis, fibrosis and cirrhosis in the liver." | ( Bae, M; Lee, JY; Park, YK, 2018) |
| "Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders." | ( Badiali, S; Carlsson, LMS; Cespiati, A; Craxi, A; Dongiovanni, P; Fargion, S; Grimaudo, S; Kozlitina, J; Maggioni, M; Mancina, RM; Mannisto, V; Pelusi, S; Petta, S; Pietrelli, A; Pihlajamaki, J; Pingitore, P; Pipitone, RM; Romeo, S; Stender, S; Taube, M; Valenti, L, 2018) |
| "NAFLD is a polygenic condition but the individual and cumulative contribution of identified genes remains to be established." | ( Angelico, F; Angeloni, A; Arca, M; Bailetti, D; Baratta, F; Belardinilli, F; Ceci, F; D'Erasmo, L; De Masi, B; Del Ben, M; Di Costanzo, A; Giannini, G; Girelli, G; Montali, A; Pastori, D; Polimeni, L; Sponziello, M, 2018) |
| "The alleviation of NAFLD is mainly associated with decreases in hepatic cholesterol, TGs with polyunsaturated fatty acids, and alterations of free hepatic FFA." | ( Dai, Z; Feng, S; Gan, L; Liu, AB; Lu, W; Luo, Z; Shao, P; Sun, P; Yang, CS, 2018) |
| "NAFLD is correlated with liver-related death and is predicted to be the most frequent indication for liver transplantation by 2030." | ( Borém, LMA; Brandi, IV; Lelis, DF; Neto, JFR; Santos, SHS, 2018) |
| "Both ARLD and NAFLD are multifactorial and refer to a spectrum of disease severity, ranging from steatosis through steatohepatitis to fibrosis and cirrhosis." | ( Anstee, QM; Scott, E, 2018) |
| "NAFLD is a broad clinicopathologic spectrum ranging from simple steatosis to varying degrees of necroinflammation called nonalcoholic steatohepatitis (NASH), leading to fibrosis and subsequently to cirrhosis." | ( Alkhouri, N; Conjeevaram Selvakumar, PK; Kabbany, MN, 2018) |
| "NAFLD is a very common disease in obese children." | ( Malecka-Tendera, E; Matusik, P; Prokopowicz, Z, 2018) |
| "The hallmark of NAFLD is the hepatic accumulation of lipids, which subsequently leads to cellular stress and hepatic injury, eventually resulting in chronic liver disease." | ( Bailly-Maitre, B; Chevet, E; Hazari, Y; Hetz, C; Lebeaupin, C; Vallée, D, 2018) |
| "Furthermore, NAFLD is believed to be involved in the pathogenesis of common disorders such as type 2 diabetes and cardiovascular disease." | ( Cusi, K; Häring, HU; Stefan, N, 2019) |
| "The severity of NAFLD is associated with the risk of urolithiasis among NAFLD patients." | ( Qin, S; Wang, J; Wang, S; Wang, X; Xu, Y; Zhang, Y; Zhou, C, 2019) |
| "Once NAFLD is established, insulin resistance can promote the progression to the more severe state of liver endangerment like NASH." | ( Chao, HW; Chao, SW; Cheng, CF; Ku, HC; Lin, H, 2019) |
| "As the basis for NAFLD is excess calorie uptake and excess adipose tissue mass, the conservative therapeutic approach is weight loss by intense lifestyle change." | ( Canbay, A; Sowa, JP, 2019) |
| "NAFLD is prevalent in patients with type 2 diabetes mellitus (T2DM), yet only preliminary evidence are available on the effect of anti-diabetic agents to NAFLD in T2DM patients." | ( Weng, J, 2019) |
| "NAFLD is closely linked to dysregulated hepatic lipid metabolism." | ( Choung, S; Joung, KH; Kim, HJ; Kim, JM; Ku, BJ; Lee, ES, 2019) |
| "NAFLD is the most common chronic liver disease in United States, and an independent risk factor for mortality." | ( Shetty, A; Syn, WK, 2019) |
| "Nonalcoholic fatty liver disease is a progressive disease involving the accumulation of lipid droplets in the liver." | ( Kim, GT; Kim, YJ; Lee, DY; Park, DK; Park, HJ; Park, TS; Tran, NKS, 2019) |
| "The pathogenesis of NAFLD is complex and multifactorial." | ( Aslam, A; Khan, MY; Mihali, AB; Rawala, MS; Siddiqui, WJ, 2019) |
| "The prevalence of NAFLD is increasing in parallel with the global rise in obesity and type 2 diabetes mellitus." | ( Byrne, CD; Jennison, E; Patel, J; Scorletti, E, 2019) |
| "NAFLD is a vital health problem worldwide; however, no effective treatment is currently available for NAFLD." | ( Chen, C; Feng, Q; Hu, YY; Xin, X, 2019) |
| "NAFLD is also considered as the hepatic manifestation of metabolic syndrome." | ( Halon, A; Kaczorowski, M; Kempinski, R; Neubauer, K; Poniewierka, E, 2019) |
| "NAFLD is emerging as a predominant etiology of CLD in India, followed by ALD, HBV, and HCV." | ( Chaudhari, S; Choudhuri, G; Pawar, D; Roy, DS, 2018) |
| "NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end." | ( Alukal, JJ; Thuluvath, PJ, 2019) |
| "NAFLD is a multisystem disease that is characterized by hepatic fat accumulation due in part to dysregulated energy metabolism network through epigenetic mechanisms such as DNA methylation." | ( Johnson, R; Louw, J; Mabasa, L; Pheiffer, C; Samodien, E; Sangweni, NF, 2020) |
| "NAFLD is predicted to soon become the main cause of liver morbidity and transplantation." | ( Bulutoglu, B; Kang, YBA; Mert, S; Rey-Bedón, C; Usta, OB; Yarmush, ML, 2019) |
| "NAFLD is a still reversible phase but may evolve into steatohepatitis (NASH), cirrhosis and carcinoma." | ( De Petro, G; García-Gómez, R; Grossi, I; Lavazza, A; Monsalve, M; Patel, GA; Rezzani, R; Salvi, A; Stacchiotti, A, 2019) |
| "NAFLD is a genetic-environmental-metabolic stress-related disease of unclear pathogenesis." | ( Nagata, N; Ota, T; Xu, L, 2019) |
| "NAFLD is also generally conceived as the hepatic manifestation of the metabolic syndrome." | ( Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T, 2019) |
| "The pathogenesis of NAFLD is complex and multifactorial." | ( Chen, Y; Hong, Y; Jia, E; Jiao, J; Li, H, 2020) |
| "The occurrence of NAFLD is closely associated with abnormal lipid metabolism and implies a high risk of type 2 diabetes and cardiovascular disease." | ( Bai, M; Bao, Y; Huang, Y; Li, Y; Liang, C; Liu, L; Song, Z; Sun, L; Wang, S; Yang, H; Yi, J; Yu, C, 2020) |
| "The prevalence of nonalcoholic fatty liver is increasing due to modern lifestyle." | ( Behera, J; Guha, S; Hassan Mir, I; Myrthong, I; Nithyananthan, S; Sushmaa, D; Thirunavukkarasu, C; Valluru, L, 2020) |
| "Nonalcoholic fatty liver disease is a rapidly rising problem in the 21st century and is a leading cause of chronic liver disease that can lead to end-stage liver diseases, including cirrhosis and hepatocellular cancer." | ( Bhasin, K; Dvornikov, A; Frank, DN; Gonzalez, FJ; Gratton, E; Ir, D; Jones, BA; Krausz, KW; Levi, M; Libby, AE; Luo, Y; McManaman, JL; Myakala, K; Orlicky, DJ; Ranjit, S; Robertson, CE; Takahashi, S; Wang, D; Wang, XX; Xie, C, 2020) |
| "Nonalcoholic fatty liver disease is characterized by excessive hepatic accumulation of triglycerides." | ( Chen, YE; Cheng, S; Garcia-Barrio, MT; Guo, X; He, Y; Huang, W; Ji, L; Liu, Z; Meng, X; Pan, B; Wang, L; Xiong, X; Xu, M; Yang, H; Yin, Y; Zhao, L; Zhao, M; Zheng, L, 2020) |
| "NAFLD is a prevalent disease that can progress to organ damage like liver cirrhosis and hepatocellular carcinoma." | ( da Silva, RP; Deminice, R; Eudy, BJ, 2020) |
| "Incidence of nonalcoholic fatty liver disease is increasing worldwide." | ( Chen, CC; Chen, HW; Huang, CS; Kuo, LL; Lii, CK; Lo, CW; Yen, CC, 2020) |
| "Furthermore, NAFLD is a risk factor for cardiovascular diseases and type 2 diabetes, two of the major leading causes of morbidity and mortality in western countries." | ( Di Vincenzo, A; El Hadi, H; Pagano, C; Rossato, M; Vettor, R, 2020) |
| "NAFLD is multi-factorial in pathogenesis with some genetic predisposition." | ( Akkız, H; Delik, A; Dinçer, S, 2020) |
| "Non-obese NAFLD is common, particularly in South America and among people aged ≥45 years." | ( Fan, JG; Wong, VW; Zou, ZY, 2020) |
| "NAFLD is a worldwide problem and represents a major cause of liver injury, which can lead to liver cell death." | ( Chaichompoo, W; Kongkaew, A; Sivasinprasasn, S; Suksamrarn, A; Tocharus, C; Tocharus, J; Wikan, N, 2020) |
| "NAFLD is an epidemic affecting nearly 34% of the adult population in the US." | ( Berry, DL; Cheema, A; Chung, FL; Coia, H; Cruz, MI; Girgis, M; Hou, Y; Lee, Y; Ma, N; Pannkuk, E; Permaul, E; Rodriquez, O; Zhu, Z, 2021) |
| "NAFLD is a systemic disease that can lead to the change of glucose metabolism in some extra-hepatic tissues and organs, especially the myocardium." | ( Hu, L; Niu, R; Qiu, C; Shao, X; Wang, X; Wang, Y, 2020) |
| "NAFLD is characterized by lipid accumulation, and when sufficient excess lipids are obtained, irreversible liver injury may follow." | ( Asimakopoulou, A; Bracht, T; Buhl, EM; Engel, KM; Gassler, N; Kalampoka, S; Pinoé-Schmidt, M; Schiller, J; Sitek, B; van Helden, J; Weiskirchen, R, 2020) |
| "NAFLD is the most common chronic liver disease in developed countries, affecting approximately 25% of the general population." | ( Botello-Manilla, AE; Chávez-Tapia, NC; Nuño-Lámbarri, N; Uribe, M, 2020) |
| "Mouse models of NAFLD are useful tools for understanding the pathogenesis and progression of NAFLD and for developing drugs for its treatment." | ( Kang, JH; Toita, R, 2020) |
| "NAFLD is characterized by fat accumulation in the liver." | ( Cohen, L; Neuman, MG, 2020) |
| "NAFLD is currently the most common form of chronic liver disease; however, its complex pathogenesis is still far from being elucidated, and no definitive treatment has been established so far." | ( Giannitelli, SM; Gori, M; Merendino, N; Mozetic, P; Rainer, A; Trombetta, M; Zancla, A, 2021) |
| "NAFLD is characterized by dysregulation of lipid metabolism." | ( Sunami, Y, 2020) |
| "The prevalence of NAFLD is high in women with prior GDM." | ( Ambekar, S; Bhatia, D; Garg, V; Goyal, A; Gupta, N; Gupta, Y; Kachhawa, G; Kalaivani, M; Kandasamy, D; Kedia, S; Kubihal, S; Tandon, N, 2021) |
| "Although NAFLD is common and typically asymptomatic, screening is not currently recommended, even in high-risk patients." | ( Bader, AR; Jeske, R; Westfall, E, 2020) |
| "NAFLD is strongly associated with central obesity, diabetes, dyslipidemia and insulin resistance, and it has been considered as the hepatic manifestation of the metabolic syndrome." | ( Alberti, G; Gana, JC; Santos, JL, 2020) |
| "NAFLD is usually associated with type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, and obesity." | ( Ahadi, M; Farzanehfar, M; Masoudifar, N; Molooghi, K; Namdar, AB; Vossoughinia, H, 2021) |
| "NAFLD is associated with obesity and insulin resistance, both of which are induced by several antipsychotic medications." | ( Beauchemin, M; Bernier, E; Bouchard, C; Houseknecht, KL; May, M; Rostama, B; Vary, CPH, 2020) |
| "NAFLD is associated with high daily caloric intake and sedentary behaviour, with excessive consumption of added sugar emerging as an important contributor to NAFLD risk in children." | ( DiStefano, JK; Shaibi, GQ, 2021) |
| "NAFLD is also a contributing factor to cardiovascular and metabolic diseases." | ( Hinds, TD; Stec, DE, 2020) |
| "NAFLD is a spectrum of diseases ranging from simple steatosis to hepatic carcinoma." | ( Fierro, R; González-Márquez, H; Guéant, JL; Guéant-Rodríguez, RM; Marchal, A; Sámano-Hernández, L, 2021) |
| "Progression in NAFLD is associated with mitochondrial dysfunction and changes in metabolites associated with the urea cycle." | ( Agarwal, K; Ajaz, S; Carey, I; Gnudi, L; McPhail, MJ; Mujib, S; Napoli, S; Trovato, FM, 2021) |
| "Nonalcoholic fatty liver disease is defined as the accumulation of excessive fat in the liver in the absence of excessive alcohol consumption or any secondary cause." | ( Dobrucki, JW; Górka, J; Jura, J; Korlatowicz, A; Kotlinowski, J; Kwapisz, O; Marona, P; Miekus, K; Pydyn, N; Waligórska, A, 2021) |
| "NAFLD is correlated to a higher CVD risk which may be ameliorated by dietary interventions." | ( Corsini, A; Dongiovanni, P; Paolini, E; Ruscica, M; Sirtori, CR, 2021) |
| "NAFLD is associated with the disruption of circadian rhythms." | ( Ikaga, R; Li, D; Ogawa, H; Yamazaki, T, 2021) |
| "In theory, NAFLD is a kind of metabolic syndrome that manifests in the liver, and insulin resistance plays an important role in it." | ( Hu, H; Li, X; Meng, J; Shen, L; Shi, D; Wang, J, 2021) |
| "NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism." | ( Awasty, V; Chalasani, N; Cusi, K; Gawrieh, S; Kowdley, KV; Lai, M; Loo, N; Mohseni, R; Noureddin, M; Parmar, D; Patel, P; Schiff, E, 2021) |
| "NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population." | ( Billingsley, JM; Boutin, A; Chung, RT; Corey, KE; Feldpausch, MN; Fourman, LT; Grinspoon, SK; Hadigan, CM; Kleiner, DE; McClure, CM; Stanley, TL; Sui, SJH; Torriani, M; Zheng, I, 2021) |
| "NAFLD is linked to lower total testosterone in patients with T2DM, but likely given a common soil of insulin resistance/obesity and not from the severity of liver necroinflammation or fibrosis." | ( Barb, D; Bril, F; Cusi, K; Dayton, KA; Kalavalapalli, S; Lai, J, 2021) |
| "NAFLD is a growing public health burden." | ( Hu, Z; Jenkins, B; Koulman, A; Lenaerts, AS; Liang, TJ; Morell, CM; Park, SB; Tilson, SG; Vallier, L, 2021) |
| "Nonalcoholic fatty liver disease is a hepatic disorder with deposition of fat droplets and has a high risk of progression to steatosis-related hepatitis and irreversible hepatic cancer." | ( Eguchi, A; Hayashi, SM; Inohana, M; Kawashima, M; Kobayashi, M; Makino, E; Maronpot, RR; Masuda, S; Mizukami, S; Murayama, H; Nagahara, R; Nakamura, M; Ohtsuka, R; Shibutani, M; Takahashi, N; Uomoto, S; Yamashita, R; Yoshida, T, 2022) |
| "NAFLD is distinguished by the accumulation of triglycerides within hepatocytes." | ( Hu, Y; Li, H; Li, X; Sun, X; Wang, T; Xu, L; Yang, X; Yu, S; Zhao, B, 2021) |
| "The pathology of NAFLD is summarized as the 'two-hit' hypothesis." | ( Li, RX; Ma, YJ; Sun, XD; Sun, YT; Wang, YL; Wu, J; Zhang, YY; Zhao, CY; Zou, J, 2021) |
| "Globally, NAFLD is one of the most common liver disorders, with an estimated prevalence rate of more than 30% in men and 15% in women and an even higher prevalence in people with type 2 diabetes mellitus." | ( Birnbaumer, L; Chen, Z; Duan, J; Duan, R; Feng, Q; Gu, S; He, B; Jiang, J; Lv, K; Qin, Y; Wang, Z; Yang, C; Yang, S; Yang, Y; Zhang, L; Zhao, R, 2022) |
| "NAFLD is mediated by changes in lipid metabolism and known risk factors include obesity, metabolic syndrome, and diabetes." | ( Amoon, AT; Bastani, R; Bensinger, SJ; Flores, YN; Glenn, BA; Huertas-Vazquez, A; Lusis, AJ; May, FP; Ramírez-Palacios, P; Rivera-Paredez, B; Saab, S; Salmerón, J; Sinsheimer, JS; Su, B; Velazquez-Cruz, R; Williams, KJ, 2021) |
| "NAFLD is found in up to 80% of people with obesity and over 60% of patients with diabetes." | ( Majumdar, A; Tsochatzis, EA; Verbeek, J, 2021) |
| "NAFLD is a key component of metabolic syndrome, ranging from nonalcoholic fatty liver to NASH, and is now becoming the leading cause of cirrhosis and HCC worldwide." | ( Ding, X; Guo, J; Hu, S; Jiang, S; Lan, T; Li, H; Luo, D; Piao, S; Rong, X; Tian, S; Wang, L; Wang, W; Weng, Q; Xiao, X; Yang, Y; Yu, Y; Zhang, J; Zhu, Q, 2022) |
| "Nonalcoholic fatty liver disease is the most prevalent liver disease characterized by excessive lipid accumulation in hepatocytes." | ( Huang, Y; Huo, Z; Liang, J; Luan, H; Shen, Y; Sheng, L; Wu, F; Zhang, X, 2022) |
| "NAFLD is primarily caused by metabolic disruption of lipid and glucose homeostasis." | ( Jeong, W; Kim, H; Oh, CM; Park, J; Yun, C, 2021) |
| "NAFLD is often diagnosed in patients with dyslipidemias and type 2 diabetes; thus, an interesting correlation can be deduced between high hematic free fatty acids and glucose excess in the DNL dysregulation." | ( Damiano, F; Di Chiara Stanca, B; Giannotti, L; Gnoni, A; Gnoni, GV; Siculella, L, 2022) |
| "In addition, NAFLD is one of the major complications of type 2 diabetes associated with oxidative stress." | ( Kryl'skii, ED; Kuptsova, GN; Pashkov, AN; Popov, SS; Popova, TN; Raskina, EA; Shulgin, KK, 2022) |
| "NAFLD is more severe in females than males (P<0." | ( Cheng, Q; Shao, C; Xiang, X; Xu, Y; Zhang, S, 2022) |
| "T2DM, obesity and NAFLD are three closely inter-related pathological conditions." | ( Byrne, CD; Miao, L; Targher, G; Xu, J; Zheng, MH, 2022) |
| "NAFLD is the most common chronic liver disease in the Western world." | ( Graham, Y; Kassir, R; Leal, A; Mahawar, K; Pintar, T; Pouwels, S; Ramnarain, D; Sakran, N; Singhal, R; Yang, W, 2022) |
| "NAFLD is now recognised as one of the most common form of chronic liver diseases in developed countries with an estimated prevalence of 12-24% in the Asian population." | ( Farheen, SA; L, R; Sagar, A, 2022) |
| "Nonalcoholic steatohepatitis is the inflammatory subtype of nonalcoholic fatty liver disease with a high risk of progression to liver fibrosis." | ( Liu, J; Oba, Y; Yamano, S, 2022) |
| "NAFLD is strongly associated with obesity and insulin resistance." | ( Morral, N; Nassiri, M; Saxena, R; Yin, XM, 2022) |
| "The pathogenesis of NAFLD is a complex dysmetabolic process, following the "multiple-hit" hypothesis that involves hepatocytes excessive accumulation of triglycerides, insulin resistance (IR), increased oxidative stress, chronic low-grade inflammatory response and lipotoxicity." | ( Ciumărnean, L; Florea, M; Mărginean, C; Milaciu, MV; Petrescu, M; Popa, M; Vesa, ȘC; Vlaicu, SI, 2022) |
| "Nonalcoholic fatty liver disease is now recognized as the most common cause of chronic liver disease with an increasing prevalence in both adults and children." | ( Alisi, A; Frasinariu, O; Miron, I; Serban, R; Starcea, M; Temneanu, OR; Trandafir, LM; Vasiliu, I, 2022) |
| "NAFLD is one of the leading causes of chronic liver disease, including non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatic cellular carcinoma (HCC)." | ( Ahn, JH; Bae, MA; Choi, W; Jeon, JH; Jeong, BK; Kim, H; Kim, M; Kim, SS; Lee, BH; Lee, IK; Nam, JE; Oh, CJ; Pagire, HS; Pagire, SH; Park, J; Song, JS; Yoon, J, 2022) |
| "The prevalence of NAFLD is increasing worldwide." | ( Honda, Y; Imajo, K; Iwaki, M; Kasai, Y; Kessoku, T; Kobayashi, N; Kobayashi, T; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Takahashi, K; Tanaka, K; Yamamoto, A; Yoneda, M, 2022) |
| "Since NAFLD is a systemic metabolic disease, cooperation between diabetologists, nephrologists, cardiologists and hepatologists is also highly advised in the management of these patients." | ( Pár, A; Pár, G; Wittmann, I, 2022) |
| "Development of NAFLD is associated with BMI, LDL-C, sCr/bw and PLT changing trajectories in men; BMI, WC, TG, LDL-C, SUA and sCr/bw trends are associated an increased risk of NAFLD in women." | ( Guo, X; Halengbieke, A; Han, Y; Kong, L; Li, Q; Ni, X; Tao, L; Tong, C; Wu, Z; Yang, X; Zhang, S; Zheng, D, 2022) |
| "NAFLD is the most prevalent chronic liver disease worldwide and has emerged as a serious public health issue with no approved treatment." | ( Chen, J; Cui, B; Hou, S; Huang, Z; Jiang, Q; Kong, L; Li, P; Liu, X; Ma, C; Wan, Y; Wang, K; Wang, L; Xing, C; Xing, X; Zhao, Q, 2023) |
| "The occurrence of NAFLD is usually accompanied by a series of chronic metabolic diseases, with a prevalence rate is 25." | ( Aldhahrani, A; Soliman, MM; Zhang, L; Zhang, N; Zhou, F; Zhou, J, 2022) |
| "NAFLD is typically associated with obesity and diabetes, however it also develops in lean individuals without metabolic syndrome." | ( Farazi, PA; Fisher, KW; Hymel, E; Vlock, E, 2022) |
| "The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease." | ( Butt, RW; Chen, O; Dellinger, RW; Guarente, L; Harrison, SA; Holmes, HE; Hu-Seliger, T; Mozaffarian, D, 2023) |
| "NAFLD is viewed as a hepatic manifestation of metabolic syndrome, with humans and animal models presenting dyslipidemia, hypertension, and diabetes." | ( Araujo, LCC; Carvalho, CRO; Matos, SL; Moreira, GV; Murata, GM, 2022) |
| "NAFLD is associated with elevated serum triglycerides (TG), low-density lipoprotein cholesterol (LDL), and reduced high-density lipoprotein cholesterol (HDL)." | ( Chen, Y; Du, X; Feitosa, MF; Handelman, SK; Kuppa, A; Palmer, ND; Puentes, YM; Speliotes, EK, 2022) |
| "NAFLD is the most common complication in children with obesity." | ( Chen, J; Dai, Y; Dong, G; Fu, J; Huang, K; Lin, H; Lin, X; Ni, Y; Pu, J; Wu, W; Wu, Z; Zhang, L; Zhou, X, 2022) |
| "Lipotoxicity in nonalcoholic fatty liver disease is mediated in part by the activation of the stress kinase JNK, but whether MIF modulates JNK in lipotoxicity is unknown." | ( Cui, N; Dun, Y; Li, C; Li, D; Li, H; Liu, S; Liu, Y; Qiu, L; Ripley-Gonzalez, JW; You, B, 2022) |
| "Nonalcoholic fatty liver disease is highly associated with obesity and progresses to nonalcoholic steatohepatitis when the liver develops overt inflammatory damage." | ( Alpini, G; Awika, J; Cai, JJ; Cai, Y; Francis, H; Glaser, S; Guo, X; Han, X; Huo, Y; Kennedy, L; Li, H; Li, Q; Wu, C; Xie, L; Xu, Q; Yang, Y; Zheng, J; Zhou, J, 2023) |
| "Nonalcoholic fatty liver is a complication of pancreaticoduodenectomy (PD); however, liver fibrosis after PD is not well documented." | ( Iida, H; Maehira, H; Miyake, T; Mori, H; Nitta, N; Tani, M, 2022) |
| "The definition of NAFLD is given, its prevalence is described, methods for diagnosing its components such as steatosis, inflammation and fibrosis are described." | ( Breder, VV; Doshchitsin, VL; Dudinskaya, EN; Ershova, EV; Geyvandova, NI; Ivashkin, VT; Kodzoeva, KB; Komshilova, KA; Korochanskaya, NV; Kotovskaya, YV; Maevskaya, MV; Mayorov, AY; Mishina, EE; Nadinskaya, MY; Nikitin, IG; Pogosova, NV; Shamkhalova, MS; Shestakova, MV; Tarzimanova, AI; Tkacheva, ON; Troshina, EA, 2022) |
| "Nonalcoholic steatohepatitis is regarded as a risk factor of many liver diseases." | ( Bu, H; Takahashi, H; Wang, H; Zhao, W; Zhao, Y, 2022) |
| "Nonalcoholic steatohepatitis is regarded as a risk factor of many liver diseases." | ( Bu, H; Takahashi, H; Wang, H; Zhao, W; Zhao, Y, 2022) |
| "Nonalcoholic steatohepatitis is regarded as a risk factor of many liver diseases." | ( Bu, H; Takahashi, H; Wang, H; Zhao, W; Zhao, Y, 2022) |
| "Nonalcoholic fatty liver is one of the most common forms of liver disease and role of microRNAs (miRNAs) on this illness is currently unclear." | ( Çağıltay, E; Çavuşoğlu, T; Gökhan, A; Şirin, C; Tanoğlu, A; Tanoğlu, EG; Yeşilbaş, S, 2022) |
| "Nonalcoholic fatty liver is one of the most common forms of liver disease and role of microRNAs (miRNAs) on this illness is currently unclear." | ( Çağıltay, E; Çavuşoğlu, T; Gökhan, A; Şirin, C; Tanoğlu, A; Tanoğlu, EG; Yeşilbaş, S, 2022) |
| "Nonalcoholic fatty liver is one of the most common forms of liver disease and role of microRNAs (miRNAs) on this illness is currently unclear." | ( Çağıltay, E; Çavuşoğlu, T; Gökhan, A; Şirin, C; Tanoğlu, A; Tanoğlu, EG; Yeşilbaş, S, 2022) |
| "NAFLD is a multifactorial disease and its pathophysiology is complex and is currently challenged by the 'Multiple-hit hypothesis' that includes wider range of comorbidities rather than previously established theory of 'Two-hit hypothesis'." | ( El-Derany, MO; El-Mesallamy, HO; Gibriel, AA; Shatta, MA, 2023) |
| "NAFLD is a multifactorial disease and its pathophysiology is complex and is currently challenged by the 'Multiple-hit hypothesis' that includes wider range of comorbidities rather than previously established theory of 'Two-hit hypothesis'." | ( El-Derany, MO; El-Mesallamy, HO; Gibriel, AA; Shatta, MA, 2023) |
| "NAFLD is also the leading cause of liver cirrhosis, hepatocellular carcinoma, and death." | ( Jun, DW; Ko, E; Yoon, EL, 2023) |
| "NAFLD is also the leading cause of liver cirrhosis, hepatocellular carcinoma, and death." | ( Jun, DW; Ko, E; Yoon, EL, 2023) |
| "Although NAFLD is closely associated with obesity, inflammation, and insulin resistance, its pathogenesis remains unclear." | ( Chen, F; Hu, S; Hu, Y; Li, HW; Luo, ZP; Pan, LX; Peng, L; Wang, JP; Wang, SX; Wu, YC; Xu, T; Yang, CC; Yang, JF; Yao, Y, 2023) |
| "Although NAFLD is closely associated with obesity, inflammation, and insulin resistance, its pathogenesis remains unclear." | ( Chen, F; Hu, S; Hu, Y; Li, HW; Luo, ZP; Pan, LX; Peng, L; Wang, JP; Wang, SX; Wu, YC; Xu, T; Yang, CC; Yang, JF; Yao, Y, 2023) |
| "Nonalcoholic fatty liver disease is a major risk factor for hepatocellular carcinoma (HCC)." | ( Camarena, MDC; Dozmorov, MG; Gelsleichter, E; Komaniecki, G; Lai, Z; Lin, H; Mendoza, R; Sarkar, D; Subler, M; Windle, JJ, 2023) |
| "NAFLD is a clinicopathological syndrome characterized by hepatic steatosis, excluding ethanol and other definite liver damage factors." | ( Guo, X; Liu, Z; Wang, J; Yin, X, 2022) |
| "NAFLD is a liver disease that is caused by liver damage or extreme lipid deposition but not alcohol." | ( Cheng, J; Deng, X; Feng, H; Li, Z; Peng, Y; Shen, B; Wang, Y; Zhang, Q; Zhao, L, 2023) |
| "NAFLD is tightly associated with type 2 diabetes (T2D) and obesity." | ( Colosimo, S; Marchesini, G; Petroni, ML; Tan, GD; Tomlinson, JW, 2023) |
| "NAFLD is characterized by steatosis, hepatic inflammation, and fibrosis, which can develop into NASH." | ( Alpini, G; Carpino, G; Ceci, L; Chen, L; Ekser, B; Francis, H; Gaudio, E; Glaser, S; Kennedy, L; Kundu, D; Kyritsi, K; Meadows, V; Onori, P; Sybenga, A; Wu, C; Wu, N; Zhou, T, 2023) |
| "NAFLD is common after liver transplantation (LT) and is associated with an increased metabolic burden." | ( Boyett, S; Bui, AT; Forsgren, M; Parmar, D; Patel, S; Patel, V; Sanyal, AJ; Shaikh, F; Siddiqui, MS, 2023) |
| "NAFLD is caused by the accumulation of fat by excessive free fatty acids (FFAs) in the blood and is accompanied by hepatic damage, such as endoplasmic reticulum (ER) stress, abnormal glucose and insulin metabolism, oxidative stress, and lipoapoptosis with lipid accumulation." | ( Hong, SH; Hong, Y; Keum, BR; Kim, GH; Lee, M, 2023) |
| "NAFLD is increasingly common in early childhood, partly due to the increase in metabolic disease in this age." | ( Ibarra-Reynoso, LD; Lazo-de-la-Vega-Monroy, ML; Preciado-Puga, MD; Ruiz-Noa, Y; Salum-Zertuche, M, 2023) |
| "NAFLD is associated with metabolic syndrome, type 2 diabetes mellitus, and impaired gut health." | ( Choi, BS; Hermes, GDA; Lopez-Escalera, S; Lund, ML; Sakamoto, K; Wellejus, A, 2023) |
| "The improvement of NAFLD is related to the activation of the farnesoid X receptor (FXR)." | ( Gao, Y; Liu, C; Miao, D; Shen, C; Wang, L; Xu, T; Yu, L; Zhao, J; Zheng, Y, 2023) |
| "NAFLD is a fat accumulation disease and has significant effects on the body." | ( Ali, W; Bian, J; Bian, Y; Gu, J; Liu, Z; Ma, Y; Sun, J; Wang, T; Yuan, Y; Zou, H, 2023) |
| "Nonalcoholic fatty liver disease is the hepatic sign of metabolic syndrome." | ( Fattahi, MR; Najafi, N; Safarpour, AR; Shojaei-Zarghani, S, 2023) |
| "NAFLD is the dependent variable." | ( He, X; Huang, X; Qian, Y; Sun, T, 2023) |
| "NAFLD is characterized by an increase in hepatic de novo lipogenesis (DNL) and inadequate compensatory enhancement in fatty acid oxidation (FAO), which disturbs lipid homeostasis." | ( Liu, Z; Wang, J; Yin, X, 2023) |
| "Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity." | ( Byrne, CD; Targher, G; Tilg, H, 2023) |
| "NAFLD is characterized by an excessive hepatic lipid accumulation, as well as hepatic steatosis." | ( Chen, H; Chen, Y; Geng, Z; Huang, M; Li, L; Liu, J; Ma, L; Ma, Y; Wang, D; Wang, H; Wang, X; Wen, D; Zhang, D; Zhu, X; Zou, C, 2023) |
| Excerpt | Reference |
|---|
| "In the treatment of NAFLD, beside the conventionally used methods such as IR improvement, antioxidation and lipid metabolism improvement, other medicines such as nuclear metabolism ligands or activators, iron-chelating agents and syndrome differentiation treatment in traditional Chinese medicine also have good efficacy." | ( Xie, P; Zhang, Q; Zhou, XX, 2010) |
| "We employed a rat model of NAFLD to examine the therapeutic efficacy of dietary control and/or ATO treatment." | ( Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X, 2011) |
| "ATO treatment effectively improved NAFLD-related hyperlipidemia and inhibited liver steatosis, accompanied by modulating the expression of genes for regulating lipid metabolism." | ( Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X, 2011) |
| "Therefore, treatment of NAFLD with insulin sensitizers is likely to have a favorable effect toward hepatic steatosis and cardiovascular outcomes." | ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011) |
| "Pharmacological treatment options for nonalcoholic fatty liver disease (NAFLD) are limited." | ( Białkowska, J; Borkowska, A; Czupryniak, L; Ignaczak, A; Jabłkowski, M; Kwiecińska, E; Loba, J; Omulecka, A; Pawłowski, M; Saryusz-Wolska, M; Szymańska-Garbacz, E, 2011) |
| "Seventy of the patients with NAFLD who underwent abdominal ultrasound before and after administration of ezetimibe were followed." | ( Gotoh, T; Hashimoto, M; Kawanami, Y; Moritani, A; Shiwa, T; Yokoyama, T, 2011) |
| "Co-treatment of SAMC attenuated NAFLD-induced liver injury, fat accumulation, collagen formation and free fatty acids (FFAs)." | ( Ching, YP; Fung, ML; Liong, EC; Nanji, AA; Tipoe, GL; Xiao, J, 2013) |
| "The current best treatment of NAFLD and NASH is weight reduction with the current options being life style modifications, with or without pharmaceuticals, and bariatric surgery." | ( Campos, GM; Rabl, C, 2012) |
| "Currently there is no effective treatment for nonalcoholic fatty liver disease (NAFLD), especially hepatic fibrosis induced by type 2 diabetes." | ( Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M, 2012) |
| "Pretreatment sera from subjects with NAFLD and from adult controls without NAFLD controls (n = 8) were incubated in cysteamine and multimers were measured 1 hour later." | ( Cabrera, BL; Dohil, R; Lavine, JE; Meyer, L; Phillips, SA; Schmeltzer, S, 2012) |
| "Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
| "Three nonalcoholic fatty liver disease severities were generated in 50 rats: a control group (n=18) on a standard diet, and 2 study groups on a choline-deficient diet (n=18), with and without treatment with silymarin (n=14)." | ( Hsiong, CH; Hu, OY; Lee, JT; Lee, MS; Liao, JW; Pao, LH; Shih, CM; Shih, TY; Yin, FY, 2013) |
| "Patients with nonalcoholic fatty liver disease who were treated at our university hospital were eligible for enrolment in the study(n = 49)." | ( Hayashi, T; Hoki, T; Kato, J; Kawano, Y; Kobune, M; Kubo, T; Miyanishi, K; Sato, T; Sato, Y; Takimoto, R; Tanaka, S, 2013) |
| "Lower NAFLD activity score and larger decrease of ALT and insulin resistance after treatment were observed in group R compared with group NR." | ( Inada, Y; Itoh, Y; Kanemasa, K; Naito, Y; Okanoue, T; Sakai, K; Sumida, Y; Taketani, H; Tanaka, S; Yasui, K; Yoshikawa, T, 2013) |
| "Pharmacotherapy in NAFLD is not well validated, particularly combination therapy." | ( Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR, 2014) |
| "We established a guinea pig model of NAFLD and treated the animals with three doses of COT or 20 mg/kg/d simvastatin (a positive control drug) for 8 weeks." | ( Qin, S; Sang, H; Si, Y; Wang, J; Xu, X; Yang, N; Yao, S; Zhai, L; Zhang, Y; Zu, D, 2013) |
| "Worsening of NAFLD grade was recorded in two patients in the placebo group, but none in the group treated with tocotrienols." | ( Abu Bakar, MR; Ansari, MA; Gopalan, Y; Khan, NA; Magosso, E; Ng, BH; Shuaib, IL; Wong, JW; Yuen, KH, 2013) |
| "To observe the efficacy of Tiopronin in treatment of severe nonalcoholic fatty liver disease (NAFLD)." | ( Cheng, L; Hu, GY; Jia, RG; Qiu, L; Sun, RQ; Tang, MC; Wang, XP; Zhao, Y, 2014) |
| "30 patients with severe NAFLD were treated with Tiopronin for 3 months." | ( Cheng, L; Hu, GY; Jia, RG; Qiu, L; Sun, RQ; Tang, MC; Wang, XP; Zhao, Y, 2014) |
| "Pentoxifylline has been used to treat nonalcoholic fatty liver diseases (NAFLDs) due to its anti-tumor necrosis factor-α effects." | ( Xie, KQ; Zeng, T; Zhang, CL; Zhao, XL, 2014) |
| "Treatment of NAFLD is still in its infancy, although large controlled studies have demonstrated some efficacy for pioglitazone or vitamin E." | ( Moschen, AR; Tilg, H, 2014) |
| "To generate the NAFLD model, Sprague-Dawley rats were administered a high‑fat diet and following 12 weeks of model construction, rats were orally treated with a positive control drug and different doses of TARAP daily for 28 days." | ( Hong, Z; Liu, Y; Peng, J; Wu, J; Zhao, J; Zheng, H; Zheng, Y, 2014) |
| "In a NAFLD cell model, control treated and untreated HepG2 cells were pre-incubated with GFP-adenovirus (GFP-ad) for 12 hrs and then treated with oleic acid (OA) for 24 hrs." | ( Chen, D; Jia, L; Lin, M; Liu, Y; Meng, Q; Shi, Y; Xie, F; Yin, J, 2015) |
| "Novel probiotic therapy based on NAFLD/NASH specific microbial composition represents a promising future direction." | ( Baker, RD; Baker, SS; Zhu, L, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that currently lacks effective treatment." | ( Gao, X; Li, Y; Tang, X; Wang, J; Xia, P; Yuan, X, 2015) |
| "VSL#3 treatment induced changes in NAFLD urinary metabolic phenotype mainly at level of host amino-acid metabolism (that is, valine, tyrosine, 3-amino-isobutyrate or β-aminoisobutyric acid (BAIBA)), nucleic acid degradation (pseudouridine), creatinine metabolism (methylguanidine) and secondarily at the level of gut microbial amino-acid metabolism (that is, 2-hydroxyisobutyrate from valine degradation)." | ( Alisi, A; Baviera, G; Capuani, G; Ceccarelli, S; Gnani, D; Marini, F; Miccheli, A; Nobili, V; Praticò, G; Putignani, L; Tomassini, A, 2015) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common liver disease that currently has no standard treatment." | ( Lin, J; Wang, W; Wang, X; Zhang, Y, 2015) |
| "Totally 99 NAFLD patients of GSPDS were randomly allocated into two groups, 66 patients in the treatment group (treated with-TLR, one dose per day) and 33 patients in the control group (treated with placebos, one dose per day)." | ( Ding, Y; Xiong, Y; Yu, Q; Zhang, SS; Zhao, LQ; Zhou, T, 2015) |
| "Early identification of patients with nonalcoholic steatohepatitis may help improve patient outcomes through treatment intervention, including transplantation for those with decompensated cirrhosis." | ( Rinella, ME, 2015) |
| "Using a high fat diet-fed NAFLD model where bromodichloromethane (BDCM) was administered to induce CYP2E1-mediated oxidative stress, we show that P2X7r expression and protein levels were leptin and CYP2E1 dependent." | ( Alhasson, F; Chandrashekaran, V; Chatterjee, S; Das, S; Dattaroy, D; Diehl, AM; Michelotti, G; Nagarkatti, M; Nagarkatti, P; Seth, RK, 2016) |
| "Betaine has been proven effective in treating nonalcoholic fatty liver disease (NAFLD) in animal models, however, its molecular mechanisms remain elusive." | ( Fan, CY; Ge, CX; Kong, LD; Li, JM; Li, PQ; Xu, MX; Yu, R, 2016) |
| "Metformin treatment can improve NAFLD and decrease the level of chemerin." | ( Jiang, D; Li, L; Li, X; Lou, F; Lou, N; Pan, Z; Sun, A; Sun, F; Zhang, L; Zhuang, X, 2015) |
| "Without treatment, NAFLD may progress to hepatocellular carcinoma (HCC), a cancer with a high mortality rate." | ( Chen, YJ; Jeffery, EH; Wallig, MA, 2016) |
| "Rats with NAFLD were untreated (group II, MSG-obesity group) and treated with probiotics (groups III-VII)." | ( Beregova, T; Bodnar, P; Falalyeyeva, T; Kobyliak, N; Mykhalchyshyn, G; Ostapchenko, L; Spivak, M; Virchenko, O; Yankovsky, D, 2016) |
| "Qualitative ultrasonographic NAFLD improvement in diabetic patients treated with metformin in combination with other hypoglycemic drugs is associated to change over time in weight and waist circumference." | ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016) |
| "MS and NAFLD were defined according to the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) and non-invasive fatty liver index, respectively." | ( Caroleo, B; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G, 2016) |
| "We concluded that NAFLD compromises bile excretion, a process that can be reversed by treatment with RYGB." | ( Donadelli, CA; Dos Santos, JS; Nonino, CB; Salgado Júnior, W, 2016) |
| "After establishing the NAFLD rat model and treatment for 8 weeks, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), free fatty acid (FFA), fasting blood glucose (FBG), fasting insulin (FINS) contents in blood serum, and TC, TG contents in the hepatic homogenate were measured by an automatic biochemical analyzer, and a homeostasis model assessment was applied to assess the status of IR, insulin sensitivity index (ISI), and homeostasis model assessment for insulin secretion (HOMA-IS)." | ( Chen, YF; Guo, J; Jiang, T; Jiang, WN; Li, D; Tang, CP; Wang, J; Yang, CY; Zhou, Y, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and there is an urgent need to identify effective pharmacological strategies to treat NAFLD." | ( Chen, F; Chen, L; Li, C; Lin, K; Wang, J; Xu, Q; Zhou, X; Zhu, H; Zhu, M, 2016) |
| "Here, we investigated the effect of NAFLD on the pharmacokinetics of rosiglitazone, an insulin sensitizer used in the treatment of type 2 diabetes." | ( Chandrasekaran, S; Khan, AA; Krishnan, UM; Kulkarni, NM; Mahat, MY; Malampati, S; Narayanan, S; Raghul, J, 2016) |
| "No treatment for nonalcoholic fatty liver disease (NAFLD) has been approved by regulatory agencies." | ( Barlow, SE; Brunt, EM; Clark, JM; Doo, E; Jain, AK; Karpen, SJ; Kleiner, DE; Kohli, R; Lavine, JE; Molleston, JP; Murray, KF; Neuschwander-Tetri, BA; Rosenthal, P; Schwimmer, JB; Tonascia, J; Van Natta, ML; Vos, MB; Whitington, PF; Wilson, LA; Xanthakos, SA, 2016) |
| "We randomly assigned 73 patients with NAFLD-confirmed by ultra-sonography to 12 weeks of treatment with hypocaloric diet (reduction of 500 kcal per day) plus 25 µg of calcitriol supplement or a hypocaloric diet plus placebo." | ( Agah, S; Hosseini, AF; Lorvand Amiri, H; Mousavi, SN; Shidfar, F, 2016) |
| "Although the mainstay of treatment of NAFLD is weight loss, it is hard to maintain, prompting the need for pharmacotherapy as well." | ( Rotman, Y; Sanyal, AJ, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is now considered to be the most common liver disease in the Western world and has no approved pharmacological therapy." | ( Auwerx, J; Gariani, K; Jha, P; Katsyuba, E; Kim, JT; Kim, KS; Kim, YK; Lemos, V; Menzies, KJ; Perino, A; Rubbia-Brandt, L; Ryu, D; Schoonjans, K; Shong, M; Stein, S; Vijgen, S; Yi, HS; Zhang, H, 2017) |
| "n-3 PUFA decreased several markers of NAFLD; however, there was a lower observed efficacy in NASH treatment." | ( Kelley, NS, 2016) |
| "The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options." | ( Jun, DW; Nguyen, MH; Oh, H; Saeed, WK, 2016) |
| "The morbidity of NAFLD is seeing an increase year by year in the world, and it is a common cause of chronic hepatic disease and lacks effective treatment." | ( Lu, LG; Ma, ZZ, 2016) |
| "ADIPOQ methylation rate in the NAFLD group was significantly higher than in the control group, which was declined slightly following curcumin treatment." | ( Cai, B; Cao, CY; Chen, HT; Chen, WJ; Du, YL; Li, YY; Nie, YQ; Zhou, YJ, 2016) |
| "The rats in the NAFLD model were induced by feeding a high fat diet for 12 weeks and the in vitro cell model of hepatocyte steatosis was induced by treating L‑02 cells with oleic acid for 24 h." | ( Ding, QL; He, YJ; Lou, XW; Qiu, H; Wang, B; Xing, JC; Yang, RN; Zhang, MY; Zhu, YR, 2017) |
| "Treatment of NAFLD in rats by curcumin may be mediated by the decrease of visfatin and the increase of non-alcoholic fatty liver disease." | ( Chen, Y; Kang, M; Li, C; Li, J; Zhong, X, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common liver disease, which has no standard treatment available." | ( Bian, L; Chen, XJ; Dong, XQ; Li, MG; Liang, H; Liu, WJ; Ma, LQ; Wen, ML; Wu, SM; Zhao, JY; Zhu, YZ; Zou, CG, 2017) |
| "When the NAFLD model was successfully induced by administering a high-fat diet, body weight, insulin resistance and dyslipidemia were significantly increased." | ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017) |
| "For successful treatment for nonalcoholic steatohepatitis (NASH), it may be important to treat the individual causative factors." | ( Feng, GG; Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kitaura, Y; Kohama, T; Kuzuya, T; Lingyun, M; Luo, F; Nakano, I; Shimomura, Y, 2017) |
| "Analysis was intention-to-treat." | ( Katsinelos, P; Kountouras, J; Mantzoros, CS; Polymerou, V; Polyzos, SA, 2017) |
| "Further research in liver tissues from NAFLD mice and NCTC 1469 cells stressed by lipotoxicity showed wogonin treatment reduced inflammatory response by lowering interleukin-6 (IL-6) and tumor necrosis factor α (TNFα), alleviated oxidative stress by preventing the accumulation of oxidative product malondialdehyde (MDA) and strengthening the anti-oxidative capacity of glutathione (GSH), Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPX)." | ( Chen, J; Hu, X; Hu, Y; Liu, J; Wang, Y; Xu, Y; Yuan, Y; Zhou, F, 2017) |
| "Therapy for nonalcoholic steatohepatitis (NASH) is limited." | ( Arab, JP; Arrese, M; Barrera, F; Brandan, E; Cabello-Verrugio, C; Cabrera, D; Feldstein, AE; Hernandez, A; Moshage, H; Pizarro, M; Povero, D; Solís, N; Torres, J; Wree, A, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) presents with growing prevalence worldwide, though its pharmacological treatment remains to be established." | ( Barreto, AB; Graus-Nunes, F; Mandarim-de-Lacerda, CA; Rachid, TL; Souza-Mello, V; Veiga, FMS, 2017) |
| "In a rat model of NAFLD, DNP-LC-gel treated rats reduced hepatic steatosis, liver triglyceride content, plasma triacylglycerol (TG) and total cholesterol (TC) content." | ( Fu, Y; Gong, T; Song, X; Wei, G; Zhang, Q, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver morbidity and mortality, and there is still no proven effective therapy." | ( El-Kerdasy, HI; Hussien, NI; Ibrahim, ME, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the alarmingly rising clinical problems in the 21st century with no effective drug treatment until now." | ( Abd Elwahab, AH; Ramadan, BK; Schaalan, MF; Tolba, AM, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) is known to be a health-related problem; there is no proven treatment for NAFLD." | ( Akbarieh, S; Gohari, S; Heydari, AH; Jafari, S; Jameshoorani, M; Sajedi, B; Yaghoubi, M, 2017) |
| "The diagnosis of NAFLD was according to the clinical diagnosis of the Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease in 2008." | ( Chen, H; Gong, L; Luo, R; Peng, B; Ren, W; Wang, Y; Zheng, X, 2017) |
| "Pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) has not yet been approved by the US Food and Drug Administration." | ( Mao, YM; Tang, JT, 2017) |
| "Patients with nonalcoholic steatohepatitis, differing by the TNF gene -308G>A marker genotype, differ by the time course of the markers of hepatocellular damage (ALT, AST), activity of hepatocyte apoptosis (tissue polypeptide-specific antigen), and activation of specific humoral immunity (γ-globulin) in response to therapy with ursodeoxycholic acid in a dose of 10-15 mg/kg over 4-6 weeks." | ( Dudanova, OP; Kurbatova, IV; Topchieva, LV, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is becoming one of the world's most common chronic liver diseases in childhood, yet no therapy is available that has been approved by the food and drug administration (FDA)." | ( Jiang, X; Ke, Y; Liu, S; Pan, X; Shao, Y; Shi, T; Sun, J; Xi, J; Yang, X; Zhang, J; Zhou, H; Zhuang, R, 2018) |
| "KK‑Ay mice were used to produce an NAFLD model via administration of a choline‑deficient (CD) diet." | ( Ishihara, S; Ishimura, N; Kinoshita, Y; Mishiro, T; Sato, S; Tobita, H; Yazaki, T, 2018) |
| "Non-alcoholic fatty liver (NAFLD) is one the most prevalent disease worldwide which characterized by fat accumulation in liver with no established efficient therapy." | ( Gheshlaghi, GH; Goharbari, M; Jeivad, F; Sabzevari, O; Saeedi, G, 2018) |
| "The primary treatment for nonalcoholic fatty liver disease (NAFLD) in children is lifestyle change, including a healthier diet." | ( Sekkarie, A; Vos, MB; Welsh, JA, 2018) |
| "A mouse NAFLD model was established by administration of a HFD for 8 weeks." | ( Gong, J; He, K; Li, P; Niu, B; Ou, Z; Ren, G; Ye, S; Zhu, X, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related death." | ( Bisgaier, CL; Hashiguchi, T; Oniciu, DC; Shibazaki, Y, 2018) |
| "Thirty-eight of the patients had NAFLD, 29 had chronic liver disease other than NAFLD, and 17 had untreated genetic hemochromatosis." | ( Albiin, N; Beshara, S; Danielsson, O; Eggertsen, G; Hultcrantz, R; Marmur, J; Onelöv, L; Stål, P, 2018) |
| "Fifty patients with type 2 diabetes and NAFLD were randomly assigned to either the empagliflozin group (standard treatment for type 2 diabetes plus empagliflozin 10 mg daily) or the control group (standard treatment without empagliflozin) for 20 weeks." | ( Bansal, B; Choudhary, NS; Farooqui, KJ; Gill, HK; Jevalikar, G; Kaur, P; Krishan, S; Kuchay, MS; Mishra, SK; Mithal, A; Singh, MK; Wasir, JS, 2018) |
| "Treatment options for nonalcoholic fatty liver disease (NAFLD) are needed." | ( Darch, M; Floyd, S; Lee, HY; Musa-Veloso, K; Simon, R; Venditti, C; West, S, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited." | ( Butterworth, RF; Canbay, A, 2019) |
| "a total of 54 patients with a NAFLD proven biopsy were enrolled in an open prospective study and were treated with Eurosil 85® (silymarin + vitamin E) for six months." | ( Aller, R; de Luis, D; Durà, M; García Sánchez, C; Izaola, O; Laserna, C; Mora, N; Pina, M; Primo, D; Rojo, MÁ; Sigüenza, R, 2018) |
| "We found that HF/HF-induced NAFLD was prevented in adult offspring by the administration of resveratrol." | ( Huang, LT; Lai, YJ; Lin, IC; Lin, YJ; Sheen, JM; Tain, YL; Tiao, MM; Tsai, CC; Yu, HR, 2018) |
| "Pharmacological therapy for nonalcoholic fatty liver disease (NAFLD) is not approved at the present time." | ( Álvarez, D; Bustamante, A; Corbari, A; Echeverría, F; Muñoz, P; Ortiz, M; Soto-Alarcon, SA; Valenzuela, R; Videla, LA, 2018) |
| "Many NAFLD treatment guidelines recommend the use of antioxidants, especially vitamin E." | ( Adachi, T; Okada, H; Takaki, A; Uchida, D, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment." | ( Huang, W; Li, J; Xiao, Q; Xu, Y; Yang, C; Zhang, S, 2018) |
| "Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression." | ( Banerjee, R; Dennis, A; Fiore, MM; Harrison, SA; Kelly, CJ; Kelly, MD; Neubauer, S; Paredes, AH; Traber, PG; Whitehead, JM, 2018) |
| "One hundred forty-two subjects with NAFLD were enrolled in the study and randomized into six treatment groups." | ( Bonfiglio, C; Caruso, MG; Cozzolongo, R; De Leonardis, G; De Nunzio, V; Franco, I; Giannelli, G; Giannuzzi, V; Mirizzi, A; Notarnicola, M; Osella, AR; Tutino, V, 2018) |
| "Rats in an animal model of NAFLD were treated with CHLZT, and their serum levels of cholesterol (TC), triglycerides (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were detected with an automatic biochemical analyzer." | ( Li, X; Lin, M; Men, J; Wang, Q; Yuan, Y; Zhang, M, 2018) |
| "However, when NAFLD was already installed, lipid parameters were only slightly improved at 20 days of treatment, but no effect was observed on the degree of steatosis." | ( Araujo, TT; Buzalaf, MAR; Carvalho, RA; Cestari, TM; Dionizio, A; Fernandes, MS; Nogueira, FN; Oliveira, KA; Pereira, HABS; Raymundo, FS; Sabino-Arias, IT, 2019) |
| "In vivo, the animal NAFLD model was induced by feeding rats with high fat diet (HFD) for 18 weeks, and meanwhile the rats were treated with AAPC from weeks 8 to 18; In vitro experiment, the effect of AAPC on dyslipidemia induced by oleic acid (OA) in hepatic cells (HepG2) was evaluated." | ( Bai, F; Feng, Z; Lao, L; Lin, X; Pang, L; Pang, X; Qiao, Q; Sun, X; Wang, D; Wei, J, 2018) |
| "Nonalcoholic fatty liver disease (NAFLD) is increasing in worldwide prevalence, closely tracking the obesity epidemic, but specific pharmaceutical treatments for NAFLD are lacking." | ( Bang, G; Choi, C; Choi, W; Han, KH; Hwang, I; Jeong, JS; Ju, YS; Karsenty, G; Kim, H; Kim, YH; Lee, HW; Lim, A; Namkung, J; Park, HJ; Park, JY; Park, S; Suh, JM; Yadav, VK, 2018) |
| "TGJ may be a therapy for the NAFLD with T2DM rats by modulating the inflammatory response and the oxidative stress capacity." | ( Fan, Y; He, Z; Hu, A; Li, J; Xiong, W; Yin, Q; Zhang, J; Zhou, G, 2018) |
| "An in vitro NAFLD model was generated by treating HepG2 cells with oleic and palmitic acids." | ( Choi, HK; Chung, MY; Hwang, JT; Lee, J; Lee, SH; Park, JH; Shin, EJ; Song, JH, 2019) |
| "Similarly, in the NAFLD mouse model, mice fed with a high-fat diet showed reduced hepatic GLP-1R expression, which was reversed by NaB treatment and accompanied by markedly alleviated liver steatosis." | ( Chen, YW; Fan, JG; Liu, XL; Pan, Q; Xin, FZ; Yang, RX; Zhao, ZH; Zhou, D; Zhou, H, 2018) |
| "Therapy of NAFLD/NASH is easy and very complex at the same time, as the current main target is weight reduction." | ( Canbay, A; Gottlieb, A; Mosthael, W; Sowa, JP, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is now a leading cause of chronic liver disease, and there is currently no available treatment strategy." | ( Chen, W; Fan, J; Hao, Q; Jin, X; Ju, D; Liu, H; Luan, J; Mei, X; Tang, S; Wu, Z; Zai, W; Zhang, X, 2019) |
| "A high-fat diet (HFD) induced mouse NAFLD model was used with or without yangonin treatment." | ( Dong, R; Fu, T; Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Sun, H; Wang, C; Yang, X, 2019) |
| "And then, NAFLD mice were treated with daily RSV oral gavage at the dose of 100 mg/kg body weight for an additional 4 weeks." | ( Cheng, K; Li, S; Song, Z; Wang, C; Wang, T; Zhang, H; Zhang, L, 2019) |
| "Sixty-nine diabetic patients with NAFLD were randomized to 24-month treatment with placebo (35 patients) or diacerein 100 mg/day (34 patients)." | ( Cardoso, CRL; Carlos, FO; Leite, NC; Salles, GF; Viegas, BB; Villela-Nogueira, CA, 2019) |
| "Rats were fed with high fat diet and NAFLD rats were orally treated with different doses of betaine or choline or folic acid for 28 days." | ( Ali, MA; Bakir, MB; Kamel, MA; Khalifa, EA; Refaat, R; Salama, MA, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common, multifactorial liver disease that has emerged as a global challenge due to its increasing prevalence and lack of sustainable treatment options." | ( Fan, JG; Lai, JK; Qiao, L; Zhao, ZH, 2019) |
| "For T2DM combined with NAFLD patients, the saxagliptin treatment could not only effectively control blood glucose but also attenuate insulin resistance and inflammatory injury of the liver to improve fatty liver further." | ( Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS, 2019) |
| "Untreated nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) lead to irreversible liver damage." | ( Applegate, CC; Erdman, JW; Han, A; Kelly, JR; Miller, RJ; O'Brien, WD; Rowles, JL; Wallig, MA, 2019) |
| "They revealed that both improved NAFLD especially nicorandil treated proved by the reduction of liver enzymes (AST, ALT), the fatty infiltration determined histologically and biochemically (decrease liver triglycerides)." | ( Abdallah, H; Abdel Maksoud, OM; Bastawy, N; Ibrahim, W; Morsi, H; Rashed, LA; Soliman, GF, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide health problem, but no approved medical treatment exists so far." | ( Feng, Q; Hu, Y; Ni, M; Peng, J; Zhang, B; Zhao, J; Zhao, Y, 2019) |
| "Treatment of NAFLD mice with exogenous GSH alleviated OXA‑induced liver injury, possibly by ameliorating OXA‑aggravated hepatic oxidative stress and inflammation; it did not, however, attenuate OXA‑aggravated liver fibrosis." | ( Huang, X; Lin, Y; Lu, Y; Wei, J; Wu, S; Yang, C, 2019) |
| "The cellular model of NAFLD was established using OA and treated with UDCA." | ( Chen, ZY; Hong, W; Hu, J; Yao, KN; Ye, L; Zhu, XH, 2019) |
| "The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD." | ( Ajmera, VH; Aldous, JL; Aslam, S; Bassirian, S; Bettencourt, R; Blanchard, J; Boehringer, A; Cachay, E; Lee, D; Leinhard, OD; Loomba, R; Mamidipalli, A; Mangla, N; Park, D; Ramers, C; Richards, L; Singh, S; Sirlin, C; Vodkin, I, 2019) |
| "A review of NAFLD modern pharmacotherapy has been conducted." | ( Ivashkin, KV; Ivashkin, VT; Leshchenko, VI; Liusina, EO; Lunkov, VD; Maevskaya, MV; Zozula, VN, 2019) |
| "Curcumin is proposed to treat NAFLD due to its high antioxidative activity." | ( Farimani, AR; Gholami, A; Hooshmand, E; Mirhafez, SR; Nobakht M Gh, BF; Tavallaie, S, 2019) |
| "In murine models of advanced nonalcoholic steatohepatitis (NASH), the administration of T3 reduced liver triglyceride, repressed liver inflammation, and attenuated injury." | ( Bechmann, L; Best, J; Canbay, A; Claridge, LC; Coombes, JD; Gerken, G; Manka, P; Moeller, L; Sydor, S; Syn, WK; Wedemeyer, H, 2019) |
| "Pioglitazone has been used for the treatment of nonalcoholic fatty liver disease (NAFLD) related to diabetes." | ( de Mendonça, M; de Sousa, É; Dos Santos, BAC; Rodrigues, AC, 2019) |
| "The pathogenesis of nonalcoholic fatty liver disease non‑alcoholic steatohepatitis (NASH) has not been fully elucidated, and there are currently no effective treatments for NASH." | ( Chen, H; Hao, T; Tian, H; Wu, S, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD) is a global epidemic, and there is no standard and efficient therapy for it." | ( Duan, X; Gao, Y; Hu, H; Liu, W; Liu, Y; Lyu, Q; Pan, C; Qi, LW; Qian, M; Wang, L; Wang, S, 2019) |
| "T2DM-induced NAFLD and quercetin treatment models were established in vivo and in vitro." | ( Du, L; Heng, C; Jiang, Z; Lu, Q; Mao, S; Qian, X; Yang, H; Yang, T; Yin, X; Zhou, Y, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is a most common liver disorder characterized by accumulation of fat in the liver and currently there is no approved treatment for it." | ( Boppana, R; Ghaskadbi, S; Inamdar, S; Joshi, A; Malik, S, 2019) |
| "The treatment of NAFLD/NASH comprises changes in lifestyle including eating habits and exercise leading to weight loss, and drug intake such as vitamin E." | ( Kim, KI; Kim, SK; Kim, SR, 2019) |
| "Conflicting data link nonalcoholic fatty liver disease (NAFLD), a disease with no currently approved treatment, with selenium (Se) and selenoprotein P (SELENOP), a glycoprotein synthesized and primarily secreted by the hepatocytes, functioning as a Se transporter from the liver to other tissues." | ( Duntas, L; Goulas, A; Kountouras, J; Polyzos, SA, 2020) |
| "High-fat diet was employed to induce NAFLD model in rats, and six groups were set up: negative control group, reference treatment group, model group, low-dose TFCH (25 mg/kg), intermediate-dose TFCH (50 mg/kg), and high-dose TFCH (100 mg/kg)." | ( Efferth, T; Jiang, J; Shan, L; Shi, Z; Wang, L; Yan, L, 2019) |
| "Subjects with NAFLD (18-80 years, either sex) received the active or control treatment for 3 months." | ( Ammollo, CT; Barone, M; Cerletti, C; Colucci, M; Costanzo, S; De Bartolomeo, G; de Gaetano, G; Di Castelnuovo, A; Iacoviello, L; Incampo, F; Portincasa, P; Semeraro, F; Semeraro, N; Storto, M, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population." | ( Aepfelbacher, J; Branch, K; Buckless, C; Chung, RT; Corey, KE; Feldpausch, MN; Fourman, LT; Grinspoon, SK; Hadigan, CM; Kellogg, A; Kleiner, DE; Lee, H; Liu, CY; Pan, CS; Purdy, J; Stanley, TL; Torriani, M; Tsao, A; Zheng, I, 2019) |
| "Resolution of hypothyroid NAFLD was observed in livers after treatment with TQ." | ( Abdel-Hamid, AAHM; Ayuob, NN; Helal, GMM; Mubarak, WA, 2019) |
| "Non-alcoholic fatty liver diseases (NAFLD) including the severe form with steatohepatitis (NASH) are highly prevalent ailments to which no approved pharmacological treatment exists." | ( Buchheim-Dieckow, K; Castro, JP; Henkel, J; Jöhrens, K; Kleinridders, A; Laeger, T; Püschel, GP; Wardelmann, K, 2019) |
| "Nowadays, the nonalcoholic fatty liver disease represents the main chronic liver disease in the Western countries, and the correct medical therapy remains a big question for the scientific community." | ( Cossiga, V; Dallio, M; Di Sarno, R; Federico, A; Gravina, AG; Lama, S; Loguercio, C; Masarone, M; Morisco, F; Persico, M; Stiuso, P; Tuccillo, C, 2019) |
| "A subset of patients with nonalcoholic steatohepatitis (NASH) respond to treatment with vitamin E." | ( Arce-Clachar, AC; Bramlage, K; Fei, L; Mouzaki, M; Orkin, S; Su, W; Xanthakos, SA; Yodoshi, T, 2020) |
| "The existing treatments for nonalcoholic steatohepatitis (NASH) are not completely effective." | ( Ceballos, G; Hidalgo, I; Meaney, E; Nájera, N; Pérez-Durán, J; Valdespino-Vazquez, Y; Villarreal, F, 2020) |
| "Concomitant NAFLD had no impact on the long-term rates of CVS and/or BR in treated CHB patients." | ( Chaung, KT; Cheung, R; Henry, L; Hoang, JK; Le, AK; Li, J; Nguyen, MH, 2020) |
| "Given the role of the rs738409 in NAFLD diagnosis age, our results suggest that stratifying risk within populations known to have an enhanced risk of liver disease, such as Hispanic carriers of the rs738409 variant, would be effective in earlier identification of those who would benefit most from early NAFLD prevention and treatment strategies." | ( Abul-Husn, NS; Belbin, GM; Cho, J; Gignoux, CR; Kenny, EE; Loos, RJF; Moscati, A; Nadkarni, G; Sorokin, EP; Van Vleck, T; Walker, RW; Wojcik, GL, 2020) |
| "In cynomolgus monkeys with nonalcoholic fatty liver disease (NAFLD), administration of B1344 via subcutaneous injection for 11 weeks caused a profound reduction of hepatic steatosis, inflammation, and fibrosis, along with amelioration of liver injury and hepatocyte death, as evidenced by liver biopsy specimen and biochemical analysis." | ( Chen, J; Cui, A; Gao, J; Han, J; Ji, S; Li, J; Li, Y; Liu, Z; Ma, F; Ma, X; Tai, P; Wang, G; Wang, T; Xue, Y, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is difficult to manage due to the lack of effective treatments." | ( Bi, Y; Feng, W; Han, X; Liu, H; Wang, H; Wu, J; Yu, L; Zhu, D, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is a public health problem lacking an approved pharmacological treatment." | ( Del Valle-Mondragón, L; El Hafidi, M; González-Salazar, MDC; Jorge-Galarza, E; Juárez-Rojas, JG; Lopez-Uribe, AR; Medina-Urrutia, A; Posadas-Sánchez, R, 2020) |
| "Furthermore, NAFLD regressed in 52% of the treated patients (P < 0." | ( Del Valle-Mondragón, L; El Hafidi, M; González-Salazar, MDC; Jorge-Galarza, E; Juárez-Rojas, JG; Lopez-Uribe, AR; Medina-Urrutia, A; Posadas-Sánchez, R, 2020) |
| "The prevalence of nonalcoholic steatohepatitis (NASH) in menopausal women is increasing, but current treatments have not been proven effective." | ( Chayanupatkul, M; Klaikeaw, N; Sanguanrungsirikul, S; Siriviriyakul, P; Werawatganon, D; Witayavanitkul, N, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is a disease that is prevalent worldwide, and its prevention by dietary administration has recently been considered as an important strategy." | ( Chen, K; He, X; Hou, DX; Sakao, K; Xie, K, 2020) |
| "By investigating the TMZ treatment of NAFLD, it was identified that high‑fat diet (HFD) mice exhibit significant changes in several physiologic indices, including body weight, plasma lipids and glucose tolerance." | ( Li, C; Li, X; Liu, X; Lu, S; Wu, C; Zhang, Y; Zhou, H, 2020) |
| "The increasing prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide indicates the urgent need to develop novel and effective treatment strategies." | ( Fang, Q; Han, L; Jin, L; Mu, Q; Ning, G; Qian, Z; Tong, L; Wang, H; Xiang, M; Yang, J; Zhang, Y; Zhang, Z, 2020) |
| "The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25% and has continued to increase; however, no drugs have yet been approved for NAFLD treatments." | ( Hwang, SJ; Im, HJ; Kang, JY; Lee, JS; Lee, SB; Son, CG, 2020) |
| "Early evidence from diabetic NAFLD patients suggests that novel antidiabetics may lead to improvements in liver enzymes and hepatic steatosis, and this should encourage further research into possible utility of these drugs in treating NAFLD." | ( Kumar, J; Kumar, S; Memon, RS; Menezes, RG; Rizwan, T; Shahid, I; Siddiqi, TJ; Usman, MS; Zaman, M, 2021) |
| "50% of NAFLD patients (n = 20) treated with αT (200-800 IU/d) for 24 weeks had a ≥ 25% relative decrease in IHTG by magnetic resonance spectroscopy." | ( Alawad, AS; Cai, H; Fatima, SZ; Garraffo, HM; Gharib, AM; Huang, WA; Kleiner, DE; Levine, M; Lin, DD; Lingala, S; Ma, Y; Mahajan, LS; Morris, N; Ouwerkerk, R; Podszun, MC; Rolt, A; Rotman, Y; Samala, N; Schoenfeld, M; Shamburek, R; Umarova, R; Valdez, K; Violet, PC; Walter, PJ; Yang, S, 2020) |
| "Furthermore, an in vitro model of NAFLD was established using mixed fatty acids treated HepG2 cells, and APN was highly expressed in the culture solution to a concentration of 10 μg/mL." | ( Chen, T; Feng, X; Li, Y; Ma, W; Yang, Q; Zhang, S, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) affects a significant number of people worldwide and currently there are no pharmacological treatments." | ( Bedia-Diaz, G; Burris, TP; Elgendy, B; Griffett, K, 2020) |
| "To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatment with 3 statins on NAFLD/NASH using 2 non-invasive scores [NAFLD Activity Score (NAS); Fibrosis-4 score (FIB-4)]." | ( Athyros, VG; Doumas, M; Giouleme, O; Imprialos, K; Karagiannis, A; Koumaras, C; Perdikakis, E; Psallas, M; Sfikas, G, 2021) |
| "Since both those with and without NAFLD/- NASH shared several baseline characteristics, genetics may play a role in the pathogenesis of NAFLD/NASH and its treatment with statins." | ( Athyros, VG; Doumas, M; Giouleme, O; Imprialos, K; Karagiannis, A; Koumaras, C; Perdikakis, E; Psallas, M; Sfikas, G, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide, and its incidence is increasing annually, but there is currently no specific drug for treating NAFLD." | ( Chen, R; Deng, Y; Nie, H; Pan, M; Tang, K; Xie, J; Yang, Q; Zhang, Y; Zheng, C, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is a worldwide disease that progresses into steatohepatitis (NASH) that has no current effective treatment." | ( Abd-Elmonem, MM; Abdalla, AM; El Nashar, EM; El-Gamal, R; El-Nablaway, M; Elsayed, HRH; Othman, BH, 2021) |
| "Developing effective drugs to treat NAFLD is imperative." | ( Chang, TC; Chiou, WC; Huang, C; Huang, HC; Huang, YL; Lai, WH; Liang, YC; Liu, HK, 2021) |
| "A total of 50 patients with NAFLD and T2DM treated with metformin were randomized (1:1) to metformin plus add-on linagliptin (linagliptin group) or to an increased dose of metformin (metformin group) for 52 weeks." | ( Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N, 2021) |
| "Treating nonalcoholic fatty liver disease (NAFLD) is considered one of the public health priorities in the past decade." | ( Abootalebi, SN; Azarang, A; Farshad, O; Gholami, A; Heydari, R; Jamshidzadeh, A; Ommati, MM, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) incidence is higher in patients with schizophrenia and is exacerbated with antipsychotic treatment." | ( Beauchemin, M; Bernier, E; Bouchard, C; Houseknecht, KL; May, M; Rostama, B; Vary, CPH, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world with no definite treatment." | ( Al-Mousavi, Z; Asadi, S; Mahmoudi, L; Niknam, R, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease and lacks for safe and effective drug to therapy completely." | ( Fakhar, SH; Fan, X; Gu, D; Guo, Y; He, Y; Jiang, K; Li, S; Liu, B; Shi, J; Yi, H, 2021) |
| "OISE may be used to treat NAFLD through many functions, including an increase in insulin sensitivity, a decrease in lipid accumulation in the liver, suppression of inflammation, and clearance of free radicals." | ( Li, J; Liu, P; Song, X; Sun, W; Wang, M; Wang, T; Wang, X; Yang, B; Zheng, W, 2021) |
| "Then, diabetic mice with NAFLD were administered empagliflozin by gavage." | ( Chen, L; Cheng, Y; Fang, T; Han, L; Li, T; Liu, X; Meng, Z; Sun, B, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment." | ( Cabibi, D; Faldyna, M; Frohlich, J; Giallongo, S; Giannone, AG; Kovacovicova, K; Leva, L; Lo Re, O; Oben, JA; Raffaele, M; Vinciguerra, M, 2021) |
| "In this study, NAFLD model was established by feeding mice with high fat diet (HFD) for 16 weeks, and bicyclol (25 and 50 mg/kg) were orally administered for the last 4 weeks." | ( Chen, G; Liang, G; Wang, M; Wang, Y; Wang, Z; Xiao, Z; Xu, M; Yan, Y; Yang, D; Zhao, W; Zhuang, Z, 2021) |
| "IH aggravates NAFLD via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway, and which should be considered as a potential therapeutic strategy for the treatment of NAFLD with OSASH." | ( Jiang, W; Liu, H; Liu, L; Wang, L; Yue, S; Zhang, H; Zheng, P; Zhou, L; Zhou, Y, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases with no approved treatment." | ( Guo, X; Han, J; Kawai, D; Koyama, T; Motoo, Y; Satoh, T; Yamada, S; Yamaguchi, R; Zhang, J; Zhou, X, 2021) |
| "Although NAFLD/NASH are highly complex and heterogeneous conditions, most pharmacotherapy pipelines focus on a single mechanistic target." | ( An, IB; Bae, JW; Bae, SH; Cheon, JH; Cho, JW; Choi, DH; Kim, ER; Kim, JH; Kim, S; Lee, DH; Lee, M; Lee, MS; Lee, YH; Lee, YS; Nam, EJ; Oh, IJ; Oh, JY; Park, IS; Park, JS; Yang, SI, 2022) |
| "In this large cohort of patients with NAFLD and DM, use of metformin was associated with a reduced risk of HCC, whereas use of combination therapy was associated with increased risk." | ( Dai, J; El-Serag, HB; Kanwal, F; Kramer, JR; Li, L; Natarajan, Y; Yu, X, 2022) |
| "HFFCD-induced NAFLD golden hamster model was established and treated with HBMPWE." | ( Chen, J; Du, XL; Jiang, W; Li, M; Luo, YY; Ma, QG; Wang, CZ; Wang, HL; Wei, RR; Wu, G; Wu, QL; Zhao, CZ; Zhao, H; Zhong, GY; Zhong, WH; Zhu, MN; Zhu, YY, 2022) |
| "HBMPWE improved NAFLD through multiple pathways and multiple targets in body metabolism and could be used as a functional food to treat NAFLD and other lipid metabolic disorders." | ( Chen, J; Du, XL; Jiang, W; Li, M; Luo, YY; Ma, QG; Wang, CZ; Wang, HL; Wei, RR; Wu, G; Wu, QL; Zhao, CZ; Zhao, H; Zhong, GY; Zhong, WH; Zhu, MN; Zhu, YY, 2022) |
| "RA administration ameliorated NAFLD in HFD-induced obese mice and increased mouse energy expenditure." | ( Chen, YQ; Jiang, X; Wang, W; Wei, L; Zhang, J; Zhu, D; Zhu, S, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) has become prevalent worldwide, but sufficient pharmaceutical treatments for this condition are lacking." | ( Gong, Q; Gong, Y; Huang, J; Jiang, Y; Tang, Q; Zhuo, C, 2022) |
| "JLD has a protective effect against NAFLD, which may be related to its anti-pyroptosis, suggesting that JLD has the potential as a novel agent in the treatment of NAFLD." | ( Cui, WW; Gao, HL; Hao, YY; Hou, YL; Jia, ZH; Li, CR; Liu, Y; Wang, MY, 2022) |
| "At present, nonalcoholic fatty liver disease (NAFLD) does not have an approved pharmacologic therapy." | ( Anbardar, MH; Doostkam, A; Fathalipour, M; Mirkhani, H; Purkhosrow, A, 2022) |
| "The 3D model of NAFLD was induced by a fat-supplemented medium (fatty acids, FFA group) for 8 days and baicalin was administered on the 5th day." | ( Chen, Y; Duan, Z; Gao, W; Liu, S; Xu, B; Zhang, X; Zhang, Y, 2022) |
| "SV was administered to an NAFLD model constructed using a high-fat-high-carbohydrate diet (HFHC)." | ( Araujo, BP; Daliry, A; Fernandes-Santos, C; Flores, EEI; Martins, CSM; Pereira, ENGDS; Rodrigues, KL; Silvares, RR, 2022) |
| "Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy." | ( Ajluni, N; Akinci, B; Burant, CL; Chenevert, TL; Conjeevaram, HS; Eraslan, A; Esfandiari, NH; Hench, R; Hussain, HK; Innis, JW; Mantzoros, CS; McKenna, B; Meral, R; Neidert, AH; Oral, EA; Rupani, AR; Rus, D; Subauste, A; Tayeh, MK, 2021) |
| "Despite the increasing prevalence of Nonalcoholic steatohepatitis (NASH) worldwide, there is no effective treatment available for this disease." | ( Hasui, N; Ogawa, T; Sakaguchi, K; Sakamoto, Y; Shimizu, T, 2022) |
| "Patients with NAFLD having increased CIMT could be candidates not only for aggressive treatment of the liver disease, but also for cholesterol lowering strategies and aggressive treatment of cardiovascular disease risk factors." | ( Farheen, SA; L, R; Sagar, A, 2022) |
| "The alleviating effect of PCPE on NAFLD was conducted on male C57BL/6J mice fed an HFD for 16 weeks, and this effect associated with gut microbiota dependent was demonstrated by pseudo-germfree mice treated with antibiotics and fecal microbiota transplantation (FMT)." | ( Ba, Y; Chen, Q; Chen, X; Guo, Q; Hu, X; Li, X; Wang, X; Wu, X; Xiao, M; Xiong, L; Yu, L; Zhao, W; Zhao, Y, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD), the major cause of global chronic hepatic injury, has obtained increasing attention while the current drug treatment still laid safety hazards." | ( Chang, YN; Meng, XC; Zhou, YJ; Zhu, JX; Zhu, YY, 2022) |
| "The pathogenesis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) remains unclear and the effective treatments have not been explored yet." | ( Cao, Y; Deng, S; Han, M; Hao, Y; Li, L; Li, R; Liang, P; Mai, W; Qin, Q; Xie, W; Yan, J; Yan, Y; Zhang, Y; Zhou, X; Zhou, Y; Zhu, L, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common chronic disease that can cause liver deterioration if insufficiently diagnosed and untreated." | ( Ao, Y; Fu, L; Hu, H; Zhang, W; Zheng, Z, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with no currently approved treatment." | ( Che, YS; Cui, JJ; Du, P; Guo, HH; Jiang, JD; Li, R; Ma, XL; Ren, L; Tang, R; Wang, HL; Wang, LL; Wang, YN; Yan, PJ; Yu, HY; Yu, XY; Zheng, WS, 2022) |
| "The treatment of nonalcoholic fatty liver disease (NAFLD) remains very challenging." | ( Bai, Y; Cao, H; Che, Q; Chen, J; Guo, J; He, J; Qiu, S; Su, Z, 2022) |
| "Mice were fed an HFD to induce NAFLD/NASH, and bicyclol was administered as a treatment." | ( Cen, D; Chen, L; Cheng, B; Cheng, X; Jia, S; Jin, L; Shao, J; Wang, J; Wu, J; Yao, X; Zhang, C, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and the world; with no Food and Drug Administration-approved pharmacological treatment available, it remains an area of unmet medical need." | ( Caviglia, JM; Dweck, V; Saxena, D; Schwabe, RF; St Rose, K; Williams, J; Xu, F; Yan, J, 2022) |
| "Non-alcoholic steatosis (NAFLD) and steatohepatitis (NASH) are two highly prevalent human disorders for which therapy remains suboptimal." | ( Bellini, R; Biagioli, M; Bordoni, M; Di Giorgio, C; Distrutti, E; Fiorucci, S; Marchianò, S; Monti, MC; Morretta, E; Roselli, R; Urbani, G; Zampella, A, 2022) |
| "DSSG was effective for treating NAFLD patients, which could be attributed to increased activity of superoxide dismutase, a decrease of malondialdehyde as well as reduced NF‑κB activity in a NAFLD rat model." | ( Shu, S; Wang, H; Wang, Q; Xu, Z, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidities and mortality, and no effective drug treatment currently exists." | ( Chen, AY; Chen, YA; Lee, YC; Li, WY; Tyan, YC; Wu, CF; Yang, MH, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease that urgently needs effective therapy." | ( Aboul-Ela, YM; Agwa, SHA; Albadawy, R; Hamady, S; Hasanin, AH; Kamar, SS; Matboli, M; Othman, M; Raafat, MH; Yahia, YA, 2022) |
| "In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy." | ( Koperska, A; Moszak, M; Szulińska, M; Wesołek, A, 2022) |
| "Rhodiola was found to be a potential treatment for nonalcoholic fatty liver disease (NAFLD)." | ( Dun, Y; Li, D; Li, H; Liu, J; Liu, S; Qiu, L; Ripley-Gonzalez, JW; You, B; Zhang, J, 2022) |
| "HFD-fed NAFLD mice were treated with the vehicle and 80 mg/kg Sin A every day for 6 weeks." | ( Ding, L; Jiang, J; Li, Q; Liu, X; Wang, Z; Yang, L; Yu, S, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a major clinical and public health burden worldwide with no established pharmacological therapy." | ( Guan, L; Jiang, J; Liu, H; Liu, J; Peng, L; Qiao, Y; Yan, X; Zhai, Y; Zhang, Z; Zhou, W, 2022) |
| "In the NAFLD/NASH population, multivariate analysis confirmed that lenvatinib treatment was associated with a longer OS (HR 0." | ( Aldrighetti, L; Arai, T; Atsukawa, M; Burgio, V; Cabibbo, G; Casadei-Gardini, A; Cascinu, S; Cheon, J; Chon, HJ; Claudia, F; D'Alessio, A; De Cobelli, F; Di Costanzo, GG; Foschi, FG; Fukunishi, S; Hatanaka, T; Hiasa, Y; Hiraoka, A; Hirooka, M; Iavarone, M; Iijima, H; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Iwamoto, H; Joko, K; Kakizaki, S; Kang, B; Kariyama, K; Kawata, K; Koizumi, Y; Kudo, M; Kumada, T; Lonardi, S; Marra, F; Masi, G; Morishita, A; Nagano, T; Naganuma, A; Nakamura, S; Niizeki, T; Nishida, N; Nishimur, T; Nouso, K; Ochi, H; Ogawa, C; Ohama, H; Okubo, T; Pedica, F; Pinato, DJ; Piscaglia, F; Pressiani, T; Ratti, F; Rimassa, L; Rimini, M; Ryoo, BY; Sakamoto, N; Scartozzi, M; Shigeo, S; Shimada, N; Sho, T; Silletta, M; Soldà, C; Suda, G; Tada, T; Tajiri, K; Takaguchi, K; Tamburini, E; Tanaka, T; Tani, J; Toyoda, H; Tsuji, K; Tsutsui, A; Ueshima, K; Yasuda, S; Yoo, C, 2022) |
| "The early inclusion of patients with NAFLD and severe asthenic syndrome in the treatment regimen, in addition to the basic therapy of Cytoflavin, achieved a significantly high therapeutic effect in the form of normalization of the main clinical, laboratory and instrumental parameters, as well as a significant reduction in the manifestations of asthenia." | ( Eremin, MN; Ivolgin, AF; Karakozov, AG; Katenko, SV; Levchenko, OB; Molodova, AI; Pavlov, AI, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) still has no accepted pharmacological therapy." | ( Abu Ahmad, N; Hazzan, R; Mazen, E; Neeman, Z; Slim, W, 2022) |
| "181 metformin targets and 868 NAFLD disease targets were interaction analyzed, 15 core targets of metformin for the treatment of NAFLD were obtained." | ( Huang, Y; Li, C; Liang, E; Liu, T; Mao, J; Wang, X; Yan, C; Zhang, L, 2022) |
| "A common practice in the treatment of NAFLD are life-style interventions including for example increased physical activity." | ( Bertram, HC; Horsbøl Lindholm, P; Pilegaard, H; Rasmussen, MK; Thøgersen, R, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent, chronic liver diseases worldwide and currently has no specific therapy." | ( Balakrishna, K; Buvanesvaragurunathan, K; Govindaraj, R; Ignacimuthu, S; Kumar, SN; Pandikumar, P; Radha, A; Rajan, S; Shirota, O, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic fatty liver (NAFL) and a more advanced condition with inflammation/fibrosis, nonalcoholic steatohepatitis (NASH), is emerging as one of the most prevalent chronic diseases associated with the worldwide expansion of the obese population; however, there are currently only symptomatic therapy but no cure." | ( Honda, A; Ishii, I, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic fatty liver (NAFL) and a more advanced condition with inflammation/fibrosis, nonalcoholic steatohepatitis (NASH), is emerging as one of the most prevalent chronic diseases associated with the worldwide expansion of the obese population; however, there are currently only symptomatic therapy but no cure." | ( Honda, A; Ishii, I, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are serious health concerns for which lifestyle interventions are the only effective first-line treatment." | ( Amigó, N; Baiges-Gaya, G; Camps, J; Castañé, H; Jiménez-Franco, A; Joven, J; Rodríguez-Tomàs, E, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) accounts for the majority of mortal cases, while there is no currently approved therapeutics for its treatment." | ( Bugrova, AE; Ermakova, E; Fedoros, EI; Gubareva, E; Kononikhin, A; Kovaleva, O; Nikolaev, E; Orlov, A; Rukhovich, G; Sarycheva, A; Semenov, A; Semenov, S; Zherebker, A, 2022) |
| "A total of 138 NAFLD patients treated with pemafibrate at three hospitals between September 2018 and April 2021 were included." | ( Fujita, K; Himoto, T; Masaki, T; Morishita, A; Moriya, A; Nagano, T; Nakahara, M; Ono, M; Oura, K; Senoo, T; Shi, T; Tadokoro, T; Takaguchi, K; Takuma, K; Tani, J; Tatsuta, M; Tsutsui, A, 2023) |
| "In APAP-treated NAFLD mice, CAV1 expression was downregulated and Ang Ⅱ expression was upregulated compared to normal APAP-treated mice." | ( Feng, X; Fu, D; Hu, C; Huang, Y; Jiang, X; Li, Y; Wen, J; Wu, S; Xin, J; You, T, 2023) |
| "Non-alcoholic steatosis (NAFLD) and steatohepatitis (NASH) are two highly prevalent human disorders for which therapy remains suboptimal." | ( Bellini, R; Biagioli, M; Bordoni, M; Di Giorgio, C; Distrutti, E; Fiorucci, S; Marchianò, S; Massa, C; Monti, MC; Morretta, E; Roselli, R; Urbani, G; Zampella, A, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a progressive metabolic liver disease with an unknown pathogenesis and no FDA-approved drug treatment to date." | ( Li, L; Shi, Y; Song, Y; Sun, L, 2023) |
| "Human normal, NAFLD, and NASH liver samples and isolated cholangiocytes treated with control or p16 VM were evaluated for p16/E2F1/FOXO1/IGF-1 signaling." | ( Alpini, G; Carpino, G; Ceci, L; Chen, L; Ekser, B; Francis, H; Gaudio, E; Glaser, S; Kennedy, L; Kundu, D; Kyritsi, K; Meadows, V; Onori, P; Sybenga, A; Wu, C; Wu, N; Zhou, T, 2023) |
| "GAN DIO-NASH mice with biopsy-confirmed NAFLD Activity Score (NAS ≥5) and fibrosis (stage ≥F1) were biweekly administered with PF-05231023 (10 mg/kg sc) or vehicle (sc) for 12 wk." | ( Feigh, M; Gillum, MP; Hansen, HH; Jelsing, J; Nielsen, MH; Oró, D; Vrang, N, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of the global adult population and can progress to end-stage liver disease with life-threatening complications; however, no pharmacologic therapy has been approved." | ( Beloqui, A; Cani, PD; Domingues, I; Leclercq, IA; Marotti, V; Michalowski, CB; Van Hul, M; Zhang, W, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent progressive condition that lacks a specific pharmacological treatment." | ( Alegret, M; Laguna, JC; Roglans, N, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease; however, no specific pharmacological therapy has yet been approved for this condition." | ( Bonzano, S; Bossi, S; Bovolin, P; Cottone, E; De Marchis, S; Maffei, ME; Scandiffio, R; Shrestha, S, 2023) |
| "The understanding and treatment of nonalcoholic steatohepatitis (NASH) are still very limited." | ( Ke, F; Li, C; Wu, X; Zheng, J, 2023) |
| "In a nonalcoholic steatohepatitis (NASH)-induced mouse model, 6 weeks of EW-7197 and Cur5-8 co-administration alleviated liver fibrosis and improved the nonalcoholic fatty liver disease (NAFLD) activity score." | ( Ahn, CM; Chung, CH; Ha, KB; Jo, SH; Kim, DK; Lee, ES; Park, NW; Shim, S, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, without any Food and Drug Administration-approved pharmacological intervention in clinic." | ( Bai, L; Cheng, X; Cui, J; Dong, R; Hu, F; Hu, S; Hu, Y; Li, H; Liu, Z; Ma, T; Tian, S; Wang, X; Yao, X; Zhang, P; Zhang, XJ, 2023) |
| "To assess the hypothesis, NAFLD was induced in C57BL/6 mice by feeding a high-fat diet for up to two months, followed by CN administration (for three months)." | ( Deng, H; Gao, C; He, K; Huang, X; Li, P; Li, S; Liu, G; Liu, J; Nie, L; Wang, X; Xie, Y; Yang, X; Zhang, H; Zhang, Z, 2023) |
| "We evaluated the relative risk of NAFLD in the groups with discordant remnant cholesterol vs traditional lipid profiles using clinically relevant treatment targets." | ( Huang, H; Liu, Z; Miao, M; Xie, J; Xu, C; Xu, L; Zeng, Y, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and has no approved treatment." | ( Chen, S; Feng, Y; Li, X; Liang, P; Liu, H; Meng, D; Sun, S; Yin, G; Yu, W; Zhang, F; Zhang, X, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide but still lacks specific treatment modalities." | ( Jin, N; Lu, X; Nian, F; Wu, L; Xia, Q; Zhu, C, 2023) |
| "SGZT effectively treated NAFLD, and PPAR-γ, Acsl4, Plin2 and Fads1 may be the main targets of SGZT." | ( Feng, S; Han, H; Shi, M; Tang, J; Wang, L; Zhang, T, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) has no approved pharmacological treatments." | ( Alam, U; Cuthbertson, DJ; Dobbie, LJ; Hydes, TJ; Zhao, SS, 2023) |
| "The global incidence of nonalcoholic fatty liver disease (NAFLD) has been surging in recent years, however, no drug is currently approved to treat this disease." | ( Cao, P; Chen, W; Jing, X; Li, F; Luo, L; Qiu, Z; Sullivan, MA; Tian, W; Wang, Q; Wang, Y; Yu, H; Zhang, C; Zhou, Z, 2023) |
| "In light of the high prevalence of nonalcoholic fatty liver disease and obesity, treatment options for nonalcoholic steatohepatitis are of particular interest." | ( Aringazina, R; Luo, C; Samusenkov, V; Zakharova, N, 2023) |
| "The LPs further treated NAFLD by reshaping the structure of the gut microbiota, in which Desulfovibrio bacteria plays a key roles." | ( Geng, Z; Han, C; Huang, H; Li, W; Li, Z; Liu, R; Pan, X; Wang, Y; Zhang, Y; Zhao, Z; Zuo, X, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD), sarcopenia and sarcopenic obesity (SO) are highly prevalent conditions that may coexist, especially in the aging population, without any approved pharmacologic treatment for all of them." | ( Mantzoros, CS; Polyzos, SA; Vachliotis, ID, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic without effective treatment currently available." | ( Liu, Z; Wang, J; Yin, X, 2023) |
| "Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease worldwide and currently has no specific treatments." | ( Pimentel, LL; Pintado, ME; Rodríguez-Alcalá, LM; Teixeira, FS, 2023) |
| "Despite its efficacy in treating NAFLD, the precise molecular mechanism by which Erchen Decoction regulated iron ion metabolism to prevent disease progression remained poorly understood." | ( Deng, G; Gao, L; Huang, M; Li, J; Li, Y; Liao, Y; Liu, B; Liu, C; Qin, M; Shi, H; Wang, Y; Wu, C; Xu, Y; Yang, J; Yang, M; Zhang, Y; Zhao, J; Zhou, C, 2024) |
| "We constructed NAFLD model by feeding with high-fat diet for 12 weeks in vivo and Palmitic Acid + Oleic Acid treatment for 24 h in vitro." | ( Deng, G; Gao, L; Huang, M; Li, J; Li, Y; Liao, Y; Liu, B; Liu, C; Qin, M; Shi, H; Wang, Y; Wu, C; Xu, Y; Yang, J; Yang, M; Zhang, Y; Zhao, J; Zhou, C, 2024) |
| "Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic disease characterized by accumulation of lipids in the liver for which there are no effective treatment strategies." | ( Guo, F; Jiang, L; Liu, J; Shahidi, F; Sun, Y; Tsao, R; Wen, X; Xiong, H, 2023) |